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Abstract 
 
ELIZABETH MARY MCCLURE: Plasmodium falciparum malaria in pregnancy and fetal, 
newborn, and maternal outcomes among a cohort of pregnant women in coastal Kenya, 
2006 – 2009 
 (Under the direction of Steven R Meshnick, MD, PhD) 
 
Plasmodium falciparum malaria in pregnancy causes adverse pregnancy outcomes, 
most notably reduced birth weight and maternal anemia.  Preventive treatment that is safe 
during pregnancy has been shown to effectively reduce rates of malaria in pregnancy, yet in 
malaria-endemic regions rates of adverse pregnancy outcomes remain high.   
 
We sought to explore the association of malaria in pregnancy and other risk factors 
with poor outcomes, among a cohort of pregnant women who received the recommended 
preventative treatment for malaria at antenatal care. The prevalence of malaria at the first 
antenatal care visit was 11%, and malaria infection was associated with lower measures of 
fetal growth, as measured by ultrasound. Among live, term births, the mean birth weight was 
not significantly different for malaria-positive vs. malaria-negative women. However, among 
women with under-nutrition, as measured by low body-mass-index, malaria exposure was 
associated with significantly decreased birth weight (mean difference -370 grams, 95% CI -
728, -12 g). The rates of maternal anemia (hemoglobin <11.0 g/dL) and moderate/severe 
anemia (hemoglobin < 9.0 g/dL) at antenatal care were 70% and 27%, respectively. 
Moderate/severe maternal anemia at the first antenatal care visit was associated with 
malaria as diagnosed by microscopy (aRR 2.06, 95% CI 1.24, 3.44) as was high-intensity 
hookworm infection in multivariate regression (aRR 2.37, 95% CI 1.44, 3.91).   
 
 iii 
 
Our findings suggest the importance of good preventative treatment for malaria in 
pregnancy to minimize the impact of exposure to malaria on fetal and newborn growth. 
However, under-nutrition has an important role and research and programs to improve 
maternal nutritional health may be important to important to further improving birth outcomes 
in low-resource settings.  Furthermore, given the high prevalence of anemia observed in our 
study, also associated with under-nutrition, as well as hookworm, and malaria, further 
research is needed to optimize interventions around pregnancy to improve maternal and 
newborn health in malaria-endemic regions. 
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CHAPTER ONE 
INTRODUCTION AND SIGNIFICANCE 
 
Plasmodium falciparum malaria and pregnancy outcomes 
 
Malaria in pregnancy affects more than 25 million pregnant women who give birth in 
malaria-endemic areas each year, primarily in Sub-Saharan Africa, as well as many others 
who deliver in areas of low or unstable malaria transmission (Figure 1-1) [1]. Although those 
living in endemic areas 
generally develop 
immunity to malaria, 
pregnancy is a period of 
increased vulnerability. 
Beginning in the late 
1960s, published studies 
described lower birth 
weights among women 
who were infected with 
malaria during pregnancy. 
Since then, adverse outcomes which have been associated with malaria for both mother 
and newborn include maternal anemia, stillbirth, preterm birth, and low birth weight (LBW). 
Of these outcomes, maternal anemia and LBW are the most commonly documented serious 
effects associated with malaria in pregnancy [1]. Eisele et al. [2] estimated that malaria 
Figure 1-1. Malaria risk in pregnancy (Malaria Atlas 
Project) [1] 
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infection was responsible for up to 14% of all LBW infants worldwide and 11% of LBW-
related infant mortality in Sub-Saharan Africa—probably the single largest cause of adverse 
newborn outcomes in this region.  
 
Prevention strategies 
 
Because of the adverse outcomes associated with malaria in pregnancy, several 
strategies to reduce malaria have been studied [2–4]. A 2006 Cochrane review of 16 trials 
evaluating antimalarial treatment concluded that the administration of antimalarials to all 
pregnant women significantly reduced prenatal parasitemia compared with no treatment 
(relative risk [RR] 0.53; 95% confidence interval [CI], 0.33–0.86) [4]. Numerous antimalarial 
treatments have been tested; for example, the Cochrane review included trials of proguanil, 
chloroquine, and sulfadoxine-pyrimethamine (SP). However, for low-resource settings, 
where the highest burden of malaria remains, treatment ideally is low-cost and effective with 
limited dosing, and has a good safety profile. In particular, the relatively low-cost SP had 
promising results in clinical trials [5]. In 2004, WHO recommended intermittent preventive 
treatment for pregnant women with 2 doses of SP (IPTp-SP) administered at least 1 month 
apart beginning in the second trimester (3 doses for women with HIV) as standard care in 
malaria-endemic areas [5]. With the increased availability of SP and the 2004 WHO 
endorsement, many countries in Sub-Saharan Africa implemented IPTp-SP programs [3]. 
 
However, there are potential limitations to IPTp-SP. First, adherence is often 
suboptimal. Second, geographic areas of SP resistance, which are becoming increasingly 
common, were found to be associated with reduced effectiveness [6–8]. Third, there may be 
a differential impact based on other risk factors; most notably, primigravidae, who are at 
higher risk in general, also have a higher risk of adverse birth outcomes associated with 
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malaria [1,2]. Fourth, the interactions of malaria with other common infections such as HIV 
are important—especially in Sub-Saharan Africa, where HIV remains prevalent and optimal 
treatment has not been determined [9]. Fifth, there are different ways to measure malaria 
during pregnancy, including peripheral or placental blood smears, polymerase chain 
reaction (PCR), and placental histopathology; these measures are often not concordant [1]. 
 
Since the WHO guidelines were issued, a number of studies have evaluated the 
impact of intervention programs (IPTp-SP and/or insecticide-treated nets [ITNs]) on birth 
weight and other pregnancy outcomes. Given these efforts, the aim of this review was to 
review recent studies evaluating the impact of IPTp-SP, with emphasis on birth weight and 
anemia, to determine the effectiveness of SP to reduce adverse outcomes associated with 
malaria in pregnancy and factors influencing these outcomes. 
 
Methods 
A review of malaria in pregnancy and pregnancy outcomes in Sub-Saharan Africa 
was undertaken, with emphasis on recent studies of peripheral or placental malaria, 
antimalarial treatments (IPTp-SP and/or ITNs), and outcomes of birth weight and maternal 
anemia. English literature in PubMed, WHO publications, and the Cochrane database 
published since 2002 and relevant source publications were reviewed. Search terms 
included “malaria in pregnancy,” “sulfadoxine-pyrimethamine,” “insecticide-treated bed nets,” 
“anemia,” and “birth weight.” Studies conducted in Sub-Saharan Africa that included rates of 
LBW, maternal anemia, and maternal malaria infection were included; studies that did not 
quantify birth outcomes associated with the intervention or that did not quantify the 
treatment were excluded. 
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Studies of malaria and pregnancy outcomes: results 
 
Of the 197 papers screened, 84 studies were reviewed in-depth and 33 were 
included in the present review. Of these, 18 were observational studies, including cohort 
studies, and 15 were randomized clinical trials (Figure 1). The randomized clinical trials 
generally compared standard SP dosing (2 doses, as recommended by the 2004 WHO 
guidelines) with a number of different strategies: placebo; other antimalarials (chloroquine, 
mefloquine); and alternate SP-dosing strategies. Five trials also evaluated the impact of 
ITNs. Across both trials and observational studies, the primary outcomes evaluated were 
rates of placental malaria, LBW (defined as <2500 g), and maternal anemia, with several 
studies also examining preterm birth and perinatal mortality. 
 
Table 1 summarizes the randomized clinical trials of SP published since 2004 [8–22]. 
The rates of ITN use and peripheral malaria at enrollment are included for trials that 
reported these data. Next, the outcomes associated with 2 doses of SP (IPTp-SP) versus an 
alternate SP regime are given. At enrollment, the rate of untreated bed net use was 
approximately 50% while rates of ITN use were significantly lower (5%–25%). The rates of 
malaria at baseline ranged from 7% to 58%. Next, the outcomes associated with the 
treatment are reported. The placental malaria rates among those treated with IPTp-SP 
ranged from 2% to 29%. Higher dosing strategies (≥3 doses) showed lower rates of 
placental malaria infection, ranging from 2% to 8%. The alternate drug treatment groups 
(chloroquine, mefloquine) generally had similar rates of placental infection to those receiving 
IPTp-SP, while the placebo groups had significantly higher rates of infection. A similar 
relationship existed for LBW rates, which ranged from 2% to 13%, with reductions in LBW 
prevalence in the IPTp-SP group equivalent to the reductions associated with alternate drug 
treatments. Women who received more than 2 SP doses had decreased risk of LBW 
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outcome. For example, Maiga et al. [19] found that LBW rates in Mali were significantly 
lower with 3 versus 2 doses of SP (adjusted RR 0.5; 95% CI, 0.32–0.79). A study from Côte 
d’Ivoire also found that a third dose decreased risk for LBW (adjusted odds ratio [OR] 0.12, 
95% CI, 0.05–0.31) [8]. Among HIV-positive women, monthly SP dosing was superior to 2 
doses in the trial reported by Filler et al. [17] and there was a non-significant trend for better 
outcome with monthly doses compared with 2 doses in the trial reported by Hamer et al. [9]. 
Finally, maternal anemia rates ranged from 2% to approximately 30%; these differences in 
part reflected different hemoglobin levels defining moderate–severe anemia, but in general 
within each study the SP-treated group had lower anemia rates than the alternate treatment 
or placebo group. 
 
Several common findings were reported in the randomized trials. Timing of infection 
was related to risk of adverse outcomes in several studies. For example, a Burkina Faso 
cohort study evaluated outcomes by gestational age at infection and found a trend for 
decreased birth weight among women infected at less than 4 months of gestation and/or 
more than 6 months (mean birth weight decreased by 68 g [P=0.08] and 105 g [P=0.02], 
respectively) [13]. A cohort study of women in Malawi [18] found that LBW risk was higher 
among women with second-trimester infection (prevalence ratio [PR] 1.7; 95% CI, 1.1–2.7) 
than among those with third-trimester infection (PR 1.5; 95% CI, 0.9–2.7). The risk for first-
trimester infection was not evaluated [18]. Primigravidae treated with IPTp-SP were 
consistently more likely to have decreased risk for LBW compared with multigravidae. For 
example, in a Burkina Faso study, IPTp-SP use was associated with reduced risk of LBW 
among primigravidae (adjusted OR 0.11; 95% CI, 0.07–0.17) but not secundigravidae [12]. 
Finally, ITNs had an interactive effect with SP treatment in decreasing the risk of adverse 
outcomes in some, but not all, trials that examined their impact together with SP treatment 
[14,16]. 
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Next, the non-randomized studies of IPTp-SP treatment were reviewed [7,23–40] 
(Table 2). These studies included cohort, cross-sectional, and pre–post studies that 
evaluated the impact of IPTp-SP scale-up on rates of malaria in pregnancy, birth weight, 
and maternal anemia. In general, they found IPTp-SP use to be associated with reduced 
malaria rates in pregnancy. However, the impact of IPTp-SP on LBW and maternal anemia 
rates varied. Feng et al. [30] conducted a 10-year observational study in Malawi; they noted 
increasing trends of any SP use, use of more than 2 SP doses, and ITN use over time and 
corresponding decreases in rates of maternal malaria, LBW, and maternal anemia over the 
same period. By contrast, several studies noted the impact only among subpopulations—in 
particular, primigravid women and women who also used ITNs. 
 
Several explanatory variables for the variation in impact of IPTp-SP were examined. 
A Tanzanian study, which found no differences in birth weight between infants born to 
women who received IPTp-SP and those born to women who did not receive SP treatment, 
found evidence of SP-resistant malaria parasites in the geographic area in which the study 
was conducted [39]. Additionally, one of the most commonly reported modifiers was 
gravidity; primigravidae were generally more likely to experience significant benefit from SP 
treatment than were multigravidae [26,30]. Adherence to and delivery of treatment are 
important. Receipt of 2 or more doses of SP was found to be beneficial in several studies. 
For example, Aziken et al. [36] observed significantly decreased risks of maternal peripheral 
malaria, placental malaria, and LBW with 2 doses versus 1 dose versus no treatment. 
Furthermore, consistent with trials, timing of dose was associated with outcome in several 
studies, with early identification and treatment associated with decreased risk of LBW. 
However, women were often identified only late in pregnancy, and coverage of IPTp-SP—
although varied—was generally lower among the observational studies than the clinical 
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trials. Most observational studies did not conduct specific analyses of HIV-positive women; 
however, a cross-sectional study found that malaria and anemia were both reduced among 
HIV-positive women who were taking co-trimoxazole, regardless of SP treatment [31]. 
Finally, some studies observed that seasonality was a factor in effectiveness of treatment, 
with women who were pregnant during high-transmission season generally benefiting more 
from IPTp-SP treatment than those who were pregnant during low-transmission season. 
 
Several studies examined the risk of LBW stratified by gravidity [8,11,19,35] for IPTp-
SP compared with no treatment. Among primigravidae, SP treatment was consistently 
protective against LBW (RR ranged from 0.1 to 0.5). Among multigravidae, SP treatment 
showed less association with risk of LBW (RR ranged from 0.70 to 0.98). In several of these 
trials, there was no significant difference in risk of placental malaria by gravidity; however, 
SP treatment reduced the risk of placental malaria overall in several trials (RR 0.04 [95% CI, 
0.003–0.6] in the study by Gies et al. [11]; RR 0.48 [95% CI, 0.27–0.85] in the study by 
Maiga et al. [19]). 
 
 
Discussion 
The present review found that, in general, the use of IPTp-SP was beneficial, which 
is an important finding given the concerns about its impact. One of the limitations of the 
analysis was the comparison of outcomes across different types of study that had used 
various methods for determining exposure and outcome assessment. Malaria was often an 
exposure of interest as well as an outcome in relation to the impact of IPTp-SP. Additionally 
malaria was diagnosed in different studies either by blood smear or by PCR. The latter test 
is generally more sensitive but less commonly available in clinical settings. Some studies 
tested for malaria infection in peripheral blood during pregnancy or at delivery, as well as in 
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the placenta. Furthermore, maternal anemia was defined by different hemoglobin cutoff 
values and ITN use was generally determined by self-report, which may be less reliable. 
However, common elements could be determined across both randomized and non-
randomized studies, thus enabling evaluation of the relationship of SP treatment to malaria 
in pregnancy and several pregnancy outcomes. 
 
Several trends were noted across both the randomized trials and the non-
randomized studies with regard to malaria infection in pregnancy. Most studies found that 
peripheral malaria and placental malaria were both associated with adverse pregnancy 
outcomes among primigravidae, including higher risk for LBW. By contrast, multigravidae 
generally had a lower risk of LBW and other adverse pregnancy outcomes, regardless of 
malaria and SP treatment status [26,35,36,39]. Another observation was that the timing of 
infection was associated with birth outcome. Studies from Burkina Faso that evaluated 
outcomes according to gestational age at infection found a trend for decreased birth weight 
among women infected early or late in pregnancy [11,12]. The authors of a study conducted 
in Benin also reported that malaria infection detected early in pregnancy was associated 
with a lower mean birth weight compared with infection detected in mid-pregnancy [10]. 
 
Additionally, pregnancy outcomes associated with IPTp-SP use varied with regard to 
gravidity, number of SP doses received, and timing of treatment. For example, when 
examining the impact of IPTp-SP, several studies that did not find overall differences in birth 
weight associated with IPTp-SP did report a significant impact in subpopulations. A study 
from Nigeria found that placental malaria rates differed between the SP-treated group and 
the placebo group among primigravidae but not among women in their second or later 
pregnancies [33]. A randomized controlled trial that restricted enrollment to primigravidae 
found a substantial reduction in LBW among women who received SP treatment [21]. Thus, 
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first pregnancy seemed to be a relatively consistent risk factor for adverse outcomes, and 
SP treatment appeared to reduce LBW among these women. With regard to the timing of 
treatment, earlier treatment—where examined—seemed to be beneficial; however studies 
with additional late treatment also found benefit.  For example, the trial in Mali [19] and a 
Côte d’Ivoire study [25] both found that a third dose of SP—late in the third trimester, when 
significant fetal weight gain occurs—reduced risk for LBW. Additionally, trends indicated that 
an increased number of SP doses was associated with decreased risk of LBW and maternal 
anemia.  
 
The use of ITNs in addition to IPTp-SP decreased the risk of malaria infection and 
LBW in several studies. In a study in Malawi, for example, SP treatment alone was not 
associated with reduced malaria infection rates, whereas concurrent ITN use provided 
significant protection [30]. However, in a trial in the Gambia, while those who used bed nets 
had similar birth weights regardless of treatment, the mean birth weight among women who 
did not routinely use a bed net was greater for those who received SP than those who did 
not [14]. The authors speculated that, especially in geographic areas with increasing 
resistance to SP, the use of ITNs may be more protective for malaria infection. 
 
There was an overall difference in findings between clinical trials and non-
randomized studies, including those evaluating the impact of the IPTp-SP policy. As 
expected, randomized clinical trials, which had higher adherence to treatment, generally 
reported significantly better outcomes associated with SP treatment than did observational 
studies attempting to document the effectiveness of IPTp-SP in a population. Although non-
randomized studies still generally found benefit of treatment, the impact was lower than 
observed in the trials. For example, Le Port et al. [24] found that IPTp-SP significantly 
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improved outcomes in a clinical trial setting in Benin; however, when the Benin Government 
scaled-up the IPTp-SP program, although pregnancy outcomes were still improved, the 
results were far less impressive than in the trials. Increasing SP resistance has been 
reported in several areas of Africa and has been hypothesized to be a potential factor in 
lower-than-anticipated reductions in LBW and other adverse pregnancy outcomes when SP 
alone is used; however, few of the trials specifically examined this issue. As observed in 
several studies, alternate strategies, including addition of ITNs, may increase effectiveness. 
 
Steketee and Campbell conducted an ecologic evaluation of neonatal and childhood 
mortality prevalence rates associated with malaria control strategies, observing that, while 
there are numerous potential factors associated with recent health improvements in African 
countries, high coverage of malaria control intervention, especially with ITNs, has been an 
important contributor to reduced childhood mortality [41]. In light of the results from studies 
comparing the effectiveness of SP related to doses, the WHO revised its guidelines in 2012 
to recommend monthly SP treatment beginning in the second trimester for pregnant women 
in Africa [42]. Given the reduction in malaria prevalence in many geographic areas, one of 
the considerations is at what prevalence this level of presumptive treatment should be 
provided. Thus, the specific components of malaria prevention strategies are important to 
overall public health impact. 
 
Gaps in research 
Although concerns have been raised about the effectiveness of SP in improving 
pregnancy outcome (e.g., because of potential resistance and lack of adherence), studies 
conducted since 2002 collectively indicate that interventions such as IPTp-SP and/or ITNs 
during pregnancy are associated with measureable improvements in maternal and infant 
health, especially among primigravidae. Increasing the number of SP doses administered 
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improves effectiveness. However, to reduce mortality substantially, optimal strategies to 
implement IPTp-SP effectively—taking into account important common comorbidities such 
as HIV—must be developed. With concerns about increasing resistance to SP, additional 
strategies, including alternate treatments and use of ITNs, may be important for improving 
outcomes during pregnancy. It is clear that increasing standardization of both measurement 
of malaria and evaluation of implementation strategies can lead to improvements in the data 
needed to address important questions regarding strategies to reduce malaria in pregnancy 
and associated adverse outcomes. 
 
Maternal anemia and malaria and other parasitic infections 
 
In many of the geographic areas where malaria is endemic, high rates of anemia in 
pregnancy are common [43].  Estimates suggest that 55.8% (95% CI, 51.9, 59.6%) of 
women in sub-Saharan Africa have anemia in pregnancy (Figure 1-2) [43] with some 
countries within Africa having rates of maternal anemia as high as 75%.   Pregnant women 
and children are particularly among those at risk for anemia in low-resource countries.  
Maternal anemia, itself a morbidity, also increases risk for mortality from obstetric conditions 
such as postpartum hemorrhage, a leading causes of maternal mortality [44].  Additionally, 
maternal anemia has been associated with fetal, neonatal, and early childhood anemia, 
potentially increasing risk for neurodevelopmental delays in studies from both developed 
and developing countries [45-48].   
 
 12 
Figure 1-2. Global prevalence of anemia in 
pregnancy (WHO, [43]) 
Measurement of anemia 
Anemia is measured by hemoglobin (Hb) level.  In pregnancy, Hb levels decrease 
over the course of the pregnancy mostly due to increased volume expansion during 
pregnancy, thus diluting the red cells and decreasing the proportion of hemoglobin [49-54]. 
The WHO thus has classified anemia as Hb <11.0 g/dL during pregnancy (compared with 
Hb < 12.0 g/dL for the non-pregnant, adult population) [43,49].  While Hb levels are an 
efficient way to approximate anemia levels at the population level, it does not distinguish 
iron-deficiency anemia from anemia which is not associated with iron deficiency [50].  
 
In Sub-Saharan African countries, high rates of low cord Hb levels, known as fetal 
anemia, have been documented, with less research on newborn Hb levels [45-47]. 
However, international cut-offs for 
neonatal and fetal Hb levels parallel 
to those for maternal anemia have 
not yet been established, in part 
due to the challenges of 
standardized collection of fetal and 
neonatal  
blood samples [49].  In high-
resource countries, 13.5 – 19.5 g/dL 
is considered to be the normal 
range of cord Hb levels [49]. 
Several studies from Sub-
Saharan Africa have used 12.5 g/dL as the cut-off to indicate fetal hemoglobin (based on 
cord blood) [45,47].  With increasing recognition of the importance of fetal and newborn iron 
levels in relation to growth and development, further research may be warranted on fetal 
Figure 1-2. Prevalence of anemia in pregnancy [43] 
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and newborn anemia and to establish reference ranges, incorporating data from Africa, 
which may differ from high-resource countries [46]. 
 
Etiology of anemia in pregnancy 
 
Gestational anemia progresses during pregnancy as the increasing needs of the 
mother and fetus are met, the plasma expands and the concentration of hemoglobin 
decreases. However, malaria-endemic regions, many women are anemic at or prior to 
pregnancy and as a result of a number of risk factors, are at increased risk to develop 
moderate or severe anemia in pregnancy [56-64].  Anemia results from a number of 
conditions – often inter-related – prevalent in low-resource countries, infections (including 
malaria, hookworm, and other parasitic infections), inadequate nutrition, and genetic 
conditions (e.g., sickle cell anemia) [54-65].  The chronic conditions/diseases associated 
with anemia are summarized in the panel below [54].  
Chronic conditions/diseases associated with anemia 
Infection Malaria, HIV, tuberculosis, osteomyelitis, bacterial endocarditis, 
pulmonary abscess 
Parasitic infection Hookworm, ascaris, schistosomiasis 
Chronic 
noninfectious 
diseases 
Diabetes, rheumatoid arthritis, Systemic Lupus Erythematosus, 
Chrohn’s disease, ulcerative colitis, chronic liver disease, 
cirrhosis, hemoglobinopathies 
Malignancy Carcinoma, sarcoma, lymphoma, myeloma 
(from Gandopadhyay et al, 2011 [54])  
 
However, nutritional deficiency and infections, especially P. falciparum malaria and 
other parasitic infections, appear to account for the majority of anemia found in Sub-
Saharan Africa [55]. 
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Infectious etiology of anemia 
 
While studies addressing the association between P. falciparum malaria and 
maternal anemia are described above and summarized in Table 1-2, malaria infection in 
pregnancy increases risk for maternal anemia. For example, Huyn et al founded an adjusted 
OR 1.7 (p = 0.001) for anemia among those women with malaria in pregnancy [23]. As 
another example, in a study in Malawi, maternal anemia was related to the number of 
malaria episodes, with higher anemia risk among women with 3 or more infections [60].  
Malaria may also relate to fetal anemia. For example, a recent study in Malawi, found that 
the prevalence OR for fetal anemia was 1.41 (95% CI 1.05, 1.90) for malaria-positive vs. 
negative women [45]. Malaria causes anemia through hemolysis of red cells combined with 
suppression of erythropoiesis, but is not thought to cause iron-deficient anemia [66], 
although this is an area of ongoing research.  
 
Hookworm  
 
In many geographic areas where malaria is endemic, other parasitic infections, most 
notably hookworm, are also prevalent [58,67-71]. An estimated 37 million pregnant women 
are infected with hookworm each year [71]. In one example, a cross-sectional study of 
pregnant women conducted from 2000-2005 in Kenya where 42.7% were infected with P. 
falciparum, rates of infections were 30.6% for Schistosoma haematobium and 31.5% for 
hookworm [67].  
 
Hookworm may cause maternal anemia through intestinal blood loss [69-71]. 
Hookworms are generally measured through stool samples, by intensity of infection as 
measured by number of eggs per gram of stool.  The WHO has classified hookworm as 
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light, moderate or high infection, with moderate/high infections most closely associated with 
anemia in the population [70].  However, research has also suggested that there may be the 
potential for a lower threshold of infection to increase infection risk, especially in association 
with under-nutrition or among vulnerable populations [70].  
 
In 1994, the WHO first 
recommended that hookworm treatment 
be included in health care for women of 
reproductive age in geographic areas 
where hookworm was endemic; however 
the treatment (albendazole) was not 
recommended during pregnancy or 
lactation [69]. In 2002, the WHO 
reconsidered their recommendation, given 
that there was no evidence of toxicity 
[70,71]. To date, three randomized 
controlled trials have assessed treatment 
for hookworm during pregnancy (Peru; Sierra Leone; Uganda), with results suggesting that 
the recommended anti-helminthic treatment effectively reduced prevalence of hookworm 
[73-77].  However, regarding impact on maternal anemia, the trial in Uganda which 
assessed anemia by treatment arm, found no effect of treatment on anemia status [77].  In 
Kenya, as elsewhere, coverage of the WHO recommended program to eliminate hookworm 
has been inconsistent, as shown in Figure 1-3. 
 
 
Figure 1-3. Status of elimination of Lymphatic 
filarisis in Kenya, 2010 (WHO) 
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Schistosomiasis and other parasitic infections 
 
In addition to malaria and hookworm, the primary infections associated with maternal 
anemia, a number of other infections have been associated with anemia in studies 
[46,57,58,62]. For example, urogenital schistosomiasis (S. haematobium), a parasite 
present in urine which is measured as eggs/mL, has also been associated with anemia in 
some studies [78].  Treatment for schistosomiasis (praziquantel) is safe during pregnancy 
and recommended by the WHO and other organizations. 
 
Besides hookworm, other helminthes, including T. trichuria and others, have been 
associated with anemia [58,79].  As with hookworm, high-intensity infections have been 
most closely correlated with moderate/severe anemia, most commonly in studies conducted 
with school-age children. 
   
Finally, HIV has an important role in maternal anemia in Sub-Saharan Africa [e.g., 
46,62,64], but is beyond the scope of this dissertation.  
 
Role of nutrition in parasitic infection 
 
Nutritional deficiency, another important cause of maternal anemia, is common in 
malaria-endemic regions [49-57].  Malnutrition causes anemia in a number of ways. First, 
iron deficiency anemia, characterized by poor iron absorption or inadequate iron intake, is 
prevalent in low-resource countries [66].   However, iron deficiency is commonly seen in 
combination with deficiency of other micronutrients such as folic acid [54,55], which together 
contribute to anemia.  
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In addition a direct contribution to increased risk of anemia, under-nutrition may also 
be associated with increased 
vulnerability to infections, and other 
morbidities [52,59]. An example of the 
potential factors influencing nutrition 
and infection is illustrated in Figure 1-4 
[59].   In addition to the relationship 
with infections, nutrition and especially 
inadequate intake of iron-rich foods, is a 
source maternal anemia, especially in 
low-resource countries [49,59,66].  As a result, international guidelines recommend iron/folic 
acid intake during pregnancy, and especially among women who are iron-deficient [49,66]; 
however, research is ongoing to determine optimal strategies to reduce nutrition-related 
anemia. 
 
Other factors associated with anemia  
 
As noted, other maternal conditions, including chronic disease, as well as socio-
demographic factors may increase risk of maternal anemia. Reduced time between 
pregnancies also may be a risk factor for anemia, as time is required for a woman to restore 
depleted iron stores following pregnancy [49]. Thus, multigravida status compared to 
primigravida status has been associated with risk of anemia in studies [e.g., 57]. Finally, 
chronic non-infectious disease, environmental and genetic factors (e.g., sickle cell disease) 
clearly contribute to anemia [54], but are beyond the scope of this review.  
 
Figure 1-4. Interaction of nutrition and 
infection [59] 
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Research gaps and conclusions: anemia and infections 
 
Maternal anemia remains an important and common condition associated with 
maternal morbidity and increased risk of maternal mortality.  Maternal anemia is also 
associated with fetal and neonatal anemia, conditions which increase the risk of long-term 
neurodevelopmental impairment. However, the cut-offs for defining fetal/neonatal anemia is 
an area of ongoing research.  
 
P. falciparum malaria has long been recognized as a cause of anemia in pregnancy 
and effective malaria preventive treatment programs have been implemented in recent 
years.  However, in many geographic areas where malaria is endemic, other parasitic 
infections, most notably hookworm, are also prevalent. While high-intensity infections are 
associated with anemia in the general population, their contribution to maternal and fetal 
anemia has been less well studied.  Finally, under-nutrition is also recognized to have an 
important role in anemia, and may contribute both directly to increased risk of anemia and 
as well as indirectly as a risk factor for infections. The etiology of anemia, especially in low-
resource countries where many risk factors are prevalent, is complex and despite strategies 
to reduce factors related to anemia, including malaria and hookworm treatment, as well as 
provision of iron/folic acid during pregnancy, rates of maternal anemia remain high in Sub-
Saharan Africa.    
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Table 1-1 Randomized clinical trials of SP treatment in pregnancy in Sub-Saharan Africa 
Country Study 
period 
Sample 
size 
Other 
treatment 
ITN 
use, 
% 
Periph
eral 
malaria
, 
baselin
e % 
Placental malaria LBW Maternal anemia 
SP, 
% 
No 
IPT, 
% 
Other, 
% 
SP, 
% 
No 
IPT, 
% 
Other, 
% 
SP, 
% 
No 
IPT, 
% 
Other, 
% 
Benin [10] 2005–
2008 
1601 MQ 53a 7.2 4.4 — 1.7 9.8 — 8.0 20 — 16 
Burkina-Faso 
[11] 
2004–
2006 
1441 Weekly CQ 35.5 20.0 19.2 — 18.8 12.8 36.5 24.8 14 — 35 
Burkina-Faso 
[12] 
2005 423 IPT-CQ 5.4 50.8 10.6 — 15.9 11.4 — 15.6 — — — 
Burkina Faso 
[13] 
2006–
2008 
1034 Three-dose 
SP 
— — 23.8 — 46.1 — — —  —  
Côte d’Ivoire 
[8] 
2009 400 SP (no 
schedule) 
— 9 4 — 7 12 — 15 9.8 — 14.6 
Gambia [14] 2002–
2004 
2688 
multi 
Placebo 50.2 a 14.9 3 9 — 5.4 7.1 — 10.6 8.9 — 
Ghana [15] 2004–
2007 
3643 AQ; SP-AQ 24.8 58.0 28.7 — 20.8 
(AQ); 
27.6 
(SP-
AQ) 
23.8 — 19.3 
(AQ); 
22.6 
(SP-
AQ) 
4.8 — 4 
(AQ); 
16 
(SP-
AQ) 
Ghana [16] 2007–
2008 
3333 AQ-AS; ITN-
SP 
52.1 a 23 12.3 — 12.4 
(ITN-
SP); 
11.3 
(AQ-
AS) 
10.7 — 10.7 
(ITN-
SP); 
12.7 
(AQ-
AS) 
1.4 — 1.7 
(ITN); 
1.7 
(AQ-
AS) 
Malawi [17] 2002–
2005 
432 
HIV-
negative
; 266 
Monthly SP 16.2 32.9 6.3 — 2.3 13.4 — 10.6 3.4 — 1.0 
  
 
20 20
 
HIV-
positive 
Malawi [18] 2003–
2006 
1320 Monthly SP; 
AZI-SP 
60.4a 8.8 2.5 — 2.1 
(monthl
y SP); 
1.8 
(AZI-
SP) 
12.9 — 9.1 
(monthl
y SP); 
7.9 
(AZI-
SP) 
— — — 
Mali [19] 2006–
2008 
814 Three-dose 
SP 
16.7 26.7 16.7 — 8.0 13.3 — 2.1 3.3 — — 
Mozambique 
[20] 
2003–
2005 
1030 Placebo — 9 4 4 — 10 10 — — — — 
Mozambique 
[21] 
2001–
2002 
600 <21 
years of 
age, 
primipar
ous 
Placebo — 33 2.4 13.3  9.5 13.3 — — — — 
Uganda [22] 2004–
2007 
5775 ITN-SP; ITN 
alone 
— — 4.3 — 3.1 
(ITN-
SP); 
2.6 
(ITN) 
6.5 6.3 6.8 
(ITN-
SP); 
6.3 
(ITN) 
14.2 — 13.6 
(ITN-
SP); 
16.3 
(ITN) 
Zambia [9] 2003–
2004 
224 
HIV-
positive 
Monthly SP 25 17 26 — 29 15 — 12 49 — 43 
Abbreviations: AQ, amodiaquine; AS, artesunate; AZI, azithromycin; CQ, chloroquine; IPT, intermittent preventive treatment; ITN, 
insecticide-treated net; LBW, low birth weight; MQ, mefloquine; PMR, perinatal mortality rate; SP, sulfadoxine/pyrimethamine.  
a Bed net (not insecticide treated). 
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Table 1-2 Non-randomized studies of SP treatment in pregnancy in Sub-Saharan Africa 
Country Study 
period 
Sampl
e size 
ITN 
use, 
% 
≥1 SP 
dose, % 
Peripher
al 
malaria, 
% 
Placental 
malaria, 
% 
Birth weight results Maternal anemia 
Benin [23,24] 2008–
2010 
1037 100 a IPTp-SP 24 11.5 10.9% LBW, not associated 
with infection; 16% early 
positive vs 9% negative 
Infection associated with 
increased risk of anemia 
(aOR 1.6 and 1.7, 
respectively)  
Côte d’Ivoire 
[25] 
2008 2044 47.9 83.8 — 4.8 10.6% LBW, associated with 
primigravidae and placental 
malaria 
— 
Democratic 
Republic of 
Congo [7] 
2007 1393 — — — — 6.8% LBW (1 dose) vs 11.4% 
LBW (2 doses); not 
significantly different after 
adjustment 
— 
Gabon [26] 2005–
2006 
203 21 24 34.4 53.6 13% LBW overall; mean birth 
weight decreased if PM 
present (–315 g)  
53% 
Gabon [27] 2003–
2004; 
2005–
2006 
1403 51.6; 
50.2 
0 vs. 
83.2  
— — 11.7% LBW (2004) vs 10.3% 
LBW (2006). 12.6% LBW (no 
IPTp) vs 8.7% LBW (IPTp) 
4.6% (2004) vs. 5.3% 
(2006) 
Ghana [28] 2000; 
2006 
1065 — 76.5 — — 26.0 LBW (2000) vs 16.2 LBW 
(2006) (P=0.03) in 
primigravidae; multigravidae 
NS 
35% for primigravidae; 
33.5% (2000) vs. 17.8% 
(2006) in multi  
Ghana [29] 2009 363 6.3 55.6 28.4 38.6 — Severe anemia 3.5% 
(IPTp) vs. 12.4% (no 
IPTp)  
Malawi [30] 1997–
2006 
8131 14.4 
65.6 
77 
(1997); 
95 (2004) 
24(1997); 
5 (2006) 
25 
(1997); 7 
(2006) 
18% LBW (1997) vs 15% LBW 
(2006) 
— 
Malawi [31] 2005–
2009 
1142 59.6 49.7 10 — — 61.4% (no treatment) vs. 
52.4% (IPTp-SP only), 
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34.7% (IPTp-SP and co-
trimoxazole) 
Mozambique 
[32] 
2003–
2004 
7911 13.5 92.5 — — 12.5% LBW (no SP) vs 7.3% 
LBW (≥2 doses) 
3.4% (no SP) vs. 0.8% 
(≥2 doses)  
Nigeria [33] 2003–
2004 
983 1.1 — 13 13 LBW RR 1.30 (95% CI, 0.64–
2.61) in presence of PM 
— 
Nigeria [34] 2005–
2006 
500 — — — 64.4 LBW not associated with PM 
(P=0.08) 
— 
Nigeria [35] 2007–
2008 
800 20.1 SP — — Increased risk of LBW with 
non-use of IPTp-sp (aOR: 2.27 
[95% CI, 0.98—5.28]) 
— 
Nigeria [36] 2009 741 — Case–
control 
8.9 (2 
doses); 
16.3 (1 
dose); 
19.1 
(none) 
5.2 (2 
doses); 
19.3 (1 
dose); 
22.6 
(none) 
11% (IPTp-SP) vs.  23% 
(none)  
1.6% (IPTp-SP) vs. 
10.8% (none)  
Senegal [37] 2004 692 — — — 10 2684 g (malaria positive) vs. 
3085 g (malaria negative) 
— 
Senegal [38] 2000; 
2007 
965 0.7–
0.8 
— — — 9.5% pre- vs. 7.7% post-IPTp-
SP   
 
Tanzania [39] 2002; 
2005 
880 15.5 — — — 9%–12.8% vs. 15.7% (aOR for 
IPTp vs. none 0.53 (0.23–
1.19) 
4.6% vs. 7.4%  
Uganda [40] 2003–
2005 
2785 — — 49.5; 
17.6  
— — — 
Abbreviations: aOR, adjusted odds ratio; IPTp, intermittent preventive treatment in pregnancy; LBW, low birth weight; PM, 
placental malaria; RR, risk ratio; SP, sulfadoxine/pyrimethamine. 
a All women received an ITN and IPTp-SP, per country guidelines. 
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CHAPTER TWO 
BACKGROUND AND SPECIFIC AIMS 
 
Background 
 
More 100 years ago adverse pregnancy outcomes were first reported in association 
with malaria and in the 1960’s, the specific association of malaria and low birth weight was 
reported in Sub-Saharan Africa  [1,78]. Since then, numerous studies have confirmed an 
association between malaria in pregnancy and low birth weight as well as other adverse 
neonatal and maternal outcomes, but most notably maternal anemia [2,59].  Treatments to 
reduce malaria were established to be safe during pregnancy and, since 2004, international 
guidelines have recommended routine preventive treatment during pregnancy [42].  
However, in the context of preventative treatment, few studies have examined the role of 
malaria in pregnancy on pregnancy outcomes. This study sought to describe the association 
of malaria and birth weight and maternal anemia, among a cohort who receive the 
recommended preventive treatment for malaria in pregnancy.   
 
Specific Aims 
Given the potential pathways by which malaria infection during pregnancy may affect 
birth outcomes, the primary objective of this study is to evaluate the associated risk of 
malaria infection in pregnancy on maternal, fetal and birth outcomes in a malaria-endemic 
area, in the context of preventive treatment for malaria in pregnancy.   
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Specific Aim I 
To describe the association between malaria infection during pregnancy and fetal 
growth, uteroplacental measures, and birth weight among a cohort in a malaria-endemic 
region with preventive treatment in pregnancy. The relationships between malaria exposure 
and these outcomes will be examined in association with other parasitic infections, maternal 
nutritional status (hemoglobin level, low body mass index [BMI]), and socio-demographic 
factors (use of bednets, gravidity, and socio-demographic status).  
 
1. Evaluate the association between malaria exposure and fetal growth, evaluating the 
timing of exposure and fetal growth patterns. 
Hypothesis: Malaria infection early in pregnancy (<22 weeks gestation) is associated 
with lower estimated fetal weight compared to late infection or no infection. 
2. Evaluate the associations between maternal nutritional status and malaria infection 
on birth outcome. 
Hypothesis: Malaria infection and poor maternal nutritional status, as measured by 
low BMI, are both associated with reduced birth weight. 
3. Evaluate the association between malaria prevention (bed net use) and treatment, 
malaria infection and birth outcomes 
Hypothesis: Those women who have not received preventive treatment prior to first 
study visit will have poorer birth outcomes compared to those who received 
preventive treatment prior to study entry. 
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Specific Aim II  
 
To estimate the association of malaria infection and hookworm infection during 
pregnancy on maternal anemia, specifically moderate/severe anemia, during pregnancy. 
1. Evaluate the association between malaria exposure, low BMI and moderate/severe 
maternal anemia during pregnancy, as measured at antenatal care. 
Hypothesis: Malaria infection during pregnancy and low BMI are both associated with 
moderate/severe maternal anemia. 
2. Given the control of malaria infection, explore the association between hookworm 
and other helminth infections and maternal anemia during pregnancy and at delivery  
Hypothesis:  Women with hookworm in pregnancy have increased risk of maternal 
anemia. 
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Figure 3-1. Study Site: Msambweni 
District, Kenya 
 
 
 
CHAPTER THREE 
METHODS 
 
Study overview 
 
The dataset utilized for this dissertation was from the Case Western Reserve 
University (CWRU) and Kenya Medical Research Institute (KEMRI) Fetal Immunity to 
Falciparum Malaria study (Christopher R. King, MD, Principal Investigator; Arlene Dent, MD, 
PhD, Co-Investigator). The Fetal Immunity study, funded by the US National Institute of 
Allergy and Infectious Disease (National Institute of Allergies and Infectious Disease; 
NCT00314899), will examine how prenatal malaria exposure affects development of 
humoral and cellular immune responses to malaria blood stage antigens from birth to 3 
years of age and to assess how prenatal exposure to malaria affects malaria infection during 
infancy, as well as growth and development during infancy.  
 
Study population 
For the study, a cohort of pregnant 
women was recruited in the Mswambweni 
Hospital in Msambweni, Coast District, located 
on the coast of Kenya (Figure 3-1, Study Site), 
a geographic area where the prevalence rate of 
malaria was approximately 10% at the time of 
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the study. From 2006 to 2009, the study team recruited pregnant women who presented for 
antenatal care (ANC) for at the study hospital and obtained follow-up for the women who 
delivered at the hospital (detailed description of the parent study available [79]).  At the time 
of the study, widespread distribution of insecticide-treated bednets (ITN’s) was ongoing, as 
part of Kenyan national policy [80]. 
 
Study recruitment and enrollment 
 
Women who presented for antenatal care (ANC) at the Mswambweni Hospital 
between 16 and 28 weeks gestation were recruited for this study (however, women at any 
gestational age, prior to delivery were enrolled). Per Kenya’s national policy, women 
received intermittent 
presumptive 
treatment (IPTp) for 
malaria, beginning in 
the second trimester 
as part of routine 
antenatal care, as 
well as iron/folate 
supplementation.  
Women with evidence of helminth infection were treated, but treatment for schistosomiasis 
was deferred until post-delivery. The birth outcomes collected were for consenting women 
with term, live births who delivered at the study hospital (Figure 3-2). (For the parent Fetal 
Immunity study, infants were followed to 36-months post-delivery, which is beyond the 
scope of this thesis.) 
Figure 3-2. Study Timeline and Data Collection, Mswambweni 
Hospital, Kenya 
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Inclusion and exclusion criteria 
Inclusion criteria 
Pregnant women were allowed to enroll irrespective of their gestational age, although 
they could not enroll at delivery because of the inability to undergo adequate consent. 
However, potential participants were strongly encouraged to come to the clinic for prenatal 
care early in the second trimester (ideally <16 weeks gestation) both to ensure adequate 
prenatal care for the mother and unborn infant. Additional inclusion criteria for the main 
study were as follows: 
• Greater than or equal to 15 years of age  
• Willingness to provide informed consent  
• Confirmed pregnancy  
• Apparent good health  
• Residence of study region 
• Consent for lab and stool samples 
 
Exclusion criteria 
Exclusion criteria for the main study included the following criteria: 
• Preterm delivery less than 34 weeks gestation 
• Failure to deliver in the hospital  
• Evidence of placenta previa  
• Maternal chorioamnionitis  
• Receipt of immunosuppressive drugs during pregnancy  
• Hemoglobin less than 6.07 g/dL  
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Additional inclusion/exclusion criteria 
The analysis set for the birth outcomes was restricted to term, singleton births.  HIV 
infection was low among this cohort and thus not otherwise evaluated.  
 
Study recruitment 
 
The number recruited and inclusion/exclusion are summarized in Figure 3-3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3. Study recruitment of pregnant mothers at first antenatal care visit, Msambweni 
District Hospital, coastal Kenya, 2006-2009 
 
The demographic and exposure variables were compared for the women enrolled 
with birth outcomes to those without birth outcome data available.  Overall, the groups did 
not have significant differences in these measures (Table 3-1). 
 
 
Antenatal care visit: Screened  
n = 813 mothers 
Birth Outcome Obtained at Hospital 
N = 515 newborns (501 mothers) 
 
Not enrolled  
n = 14 
Enrolled at Hospital 
n = 799 mothers 
    Blood Pf (n-799), Hb (n =716) 
 
Birth outcome not obtained 
Delivered elsewhere, fetal death  
n = 284 
Excluded 
Twins, stillbirth, PTB, or missing 
n = 52 
Births included 
n = 463 newborns 
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Data collection 
 
Antenatal care (ANC) visit:  At the first antenatal care visit, demographic data 
(including maternal age, marital status, educational level, tribe, household expenditure), 
medical history (Cesarean section, maternal conditions), medications used in the past 3 
months (iron, folic acid, blood, herbal medicine, malaria treatment and helminth treatment), 
date of last menstrual period, and pregnancy history (parity, and previous outcome) were 
obtained. 
 
     A maternal physical exam (height, weight, blood pressure) was performed.  Finally, 
prenatal labs were obtained: 
 Malaria by blood smear 
 Hemoglobin by Coulter counter (Beckman Coulter) 
 Dipstick (haematuria, proteinuria, and glucose) 
 Hookworm by stool (eggs per gram) 
 Schistosomiasis (eggs per mL) 
 
  Ultrasound: at least one fetal ultrasound (US) exam which measured fetal head 
circumference (HC), biparietal diameter, abdominal circumference, and femur length to 
generate fetal weight was performed at enrollment.  Ultrasound examinations were 
performed using a SonoSite 180 Plus ultrasound machine (SonoSite FujiFilm, Bothell, WA).    
 
 
 
 
 31 
 
 
 
The ultrasound variables include: 
 Placenta assessment (location, previa, grade, thickness) 
 Fetal assessment (biparietal diameter, head circumference [HC], abdominal 
circumference, fetal length, estimated gestational age, scalp thickness, organ 
calcification) 
 Doppler assessment (maximum velocity,  pulsity index (PI), resistance index (RI), 
notching, and abnormalities) for umbilical and right/left artery  
 
Delivery: At birth, the following were obtained: 
 Neonatal (birth weight, length and head circumference, Apgar scores) 
 Maternal (hemoglobin and labs including blood, urine, and stool, described above) 
 Placenta assessment (weight, length, height, proportion classified ‘abnormal’) 
 Malaria (cord, placenta or maternal by blood smear and PCR) 
 
Definitions of study variables 
 
Exposure 
Malaria: The assessment of malaria during pregnancy has important implications.  
While there are several documented types of malaria infection (P. falciparum, P. vivax, P. 
ovale, and P. malariae), P. falciparum is most closely associated with adverse pregnancy 
outcomes and the most prevalent in Sub-Saharan Africa.  Studies have shown that in most 
areas of Africa more than 80% of women testing positive for malaria were infected with P. 
falciparum [81,82].  
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Women were tested for peripheral parasitemia during pregnancy as well as at 
delivery for placental malaria infection. These both may be assessed using microscopy or 
PCR techniques. PCR is generally considered to be the gold standard, demonstrating 
greater sensitivity to detect malaria parasitemia, while misclassification is more common 
with blood smear techniques.  However, blood smear may provide a measure of clinically 
meaningful malaria infection as it detects only higher parasitemia levels, and to date is more 
feasible in field settings [83-85].  Accurate testing is important as pregnant women with 
malaria are often asymptomatic, especially those residing in malaria-endemic regions; 
however, recent studies have also suggested that there may be sub-groups of women, with 
particular co-morbidities, who are symptomatic during pregnancy [83-85]. 
 
For this study, malaria exposure was assessed at antenatal care visits (peripheral) 
and at delivery (placental, cord and maternal).  Malaria was assessed at a KEMRI lab on-
site in Kenya by microscopy using the standard Gibson stain (thick and thin slices). 
Parasitemia density was counted and also categorized as asexual and gametocytes.  
Additionally, samples were analyzed using PCR-ligase detection reaction/fluorescent 
microsphere assay at the CWRU laboratory for P. falciparum, P. malaria and P. vivax, as 
previously described [86]. For analyses of the primary outcome, peripheral malaria P. 
falciparum infection at the antenatal care visit and at delivery will be defined using the 
CWRU PCR results. Polymerase chain reaction (PCR) has been shown to be the gold 
standard and is able to detect malaria parasitemia that are not detected by blood 
microscopy [83,84].  For quality control, a sub-set of the 25 samples were reviewed by an 
independent lab (University of North Carolina at Chapel Hill) (Table 3-2).  With UNC as gold 
standard, the CWRU-PCR had 78% sensitivity and 88% specificity. 
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Furthermore, we also compared the microscopy results to the PCR-results for the 
samples with both results available. The sensitivity and specificity of the microscopy, using 
the CWRU PCR-test as a gold standard was 22% and 99% respectively, as shown in a sub-
sample with both types of diagnostic tests available (Table 3-3). 
 
Hookworm and other soil-transmitted helminthes (STH): Maternal stool samples 
were collected at ANC and delivery. Stool samples were then evaluated for presence and 
number of eggs per gram by specific organism hookworm (Ancylostoma duodenale) and 
other STH (Ascaris lumbricoides, Trichuris trichuria, Strongyloides stercoralis).  
 
Urogenital schistosomiasis: Maternal urine samples were collected and measured as 
eggs/mL to assess presence of schistomiasis and intensity of infection. Urine samples were 
evaluated for presence of urogenital schistosomiasis (Schistosomiasis haematobium). 
 
Neonatal outcomes and covariates 
Gestational age:  Gestational age was determined at enrollment using ultrasound 
measurement and date of last menstrual period.  The study team at CWRU validated these 
estimates. 
 
Fetal anthropometrics: Fetal measurements included head circumference, abdominal 
circumference, biparietal diameter (BPD) and femur length to generate fetal weight using 
Hadlock’s formula [87].  At delivery, within 24 hours of birth, birth weight, head 
circumference and length were obtained by trained study staff, with 2 measurements taken 
and the mean used.  
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Birth weight: Weight was measured at birth by trained staff using a tray scale within 
24 hours of delivery. Weight was measured twice. 
 
Rohrer’s Ponderal Index (PI): The PI is calculated as birth weight / birth length cm3 
and is a measure to approximate symmetrical vs. asymmetrical growth patterns. The 
following cut-points are used to define the newborn growth pattern [88]:  
Symmetrical growth restriction: PI = 2.32 – 2.85 
Asymmetrical growth restriction: P<2.32 
 
Fetal anemia:  Hemoglobin levels were measured at delivery from the cord. 
Fetal/neonatal anemia was defined as cord hemoglobin < 12.5 g/dL, corresponding to 2 
standard deviations below the mean level in developed countries [89]. 
 
Maternal outcomes and covariates 
Anemia: Hemoglobin levels were measured at antenatal care visits and at delivery by 
Coulter counter (Beckman Coulter Inc.). Maternal anemia is defined as a hemoglobin level < 
11 g/dL [43,90].   
Anemia was also categorized by severity according to guidelines:   
None to mild: Hb >=9 g/dL 
Moderate to severe anemia:  Hb< 9 g/dL 
   
Maternal body mass index (BMI): A measure of maternal weight divided by height2, 
the calculated BMI, adjusted for gestational age, was defined as an indicator of maternal 
nutritional status. Maternal weight was taken at the prenatal care visit by trained staff and 
height measured at the initial visit.  While low BMI pre-pregnancy BMI is defined as <18.5 
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kg/m2 (per Institute of Medicine [91]) and pre-pregnancy obesity for women is defined as 
BMI > 30 kg/m2, in this study BMI was taken at the first ANC visit (approximately 20-32 
weeks gestation), thus we defined low-BMI as the lowest percentile (less than or equal to 
the 10th percentile for the gestational age at which it was taken). The median BMI ranged 
from 23.9 kg/m2 to 25.3 kg/m2 with the range of 10th and 90th percentiles summarized in 
Table 3-4.  Further description of the analyses to define this variable is included in Appendix 
1; however, overall, these results suggest that this was a relatively homogenous group 
regarding BMI status, with most being relatively thin and no women considered to be obese. 
 
Additionally, we conducted exploratory analyses to determine whether women with 
the low BMI were at increased relative risk of infection, compared to women without low-BMI 
(Table 3-5).  Based on unadjusted analyses, low-BMI (10th percentile) did not appear to be 
an important risk factor for the main infections of interest for the study analyses (malaria, 
hookworm, and schistosomiasis). 
 
Primigravid: Defined as a woman in her first pregnancy, a potential risk factor for 
adverse birth outcomes and generally associated with increased risk of malaria infection.  
 
Preventive treatment in pregnancy (IPTp): Preventive treatment of women with SP 
beginning in the second trimester was standard of care and all women in the study received 
the recommended 2 doses.  IPTp prior to the first ANC visit was self-reported and whether it 
was provided at the visit was also collected.  
 
Table 3-6 summarizes the key exposure and outcome variables as they were defined 
for this study.  The primary exposure and outcome variables were obtained at two time 
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points, at the first ANC visit and, for a sub-set of women with term births who delivered at 
the study hospital (n= 501), at delivery for the mother, and the neonate. 
 
Data analyses 
 
Statistical analyses were performed in SAS 9.3 (SAS Institute, Cary, NC). 
Descriptive statistics (means, standard deviations, and frequencies) were computed for 
study variables. Based on evaluation of the variables, co-variates were categorized or 
collapsed into dichotomous variables for analyses. The potential confounders and effect 
measure modifiers were identified from literature review [See Chapter 2].  Finally, 
multivariate linear and log-risk models were developed to assess the association of malaria 
on the study outcomes, birth weight and anemia.  
 
Data analyses for Aim I. Maternal anemia and birth weight 
 
To evaluate the relationship of malaria at ANC with birth weight, descriptive analyses 
were performed to determine the association between potential confounders and malaria 
and birth weight (identified through literature review and directed acyclic graph, Figure 3-4). 
Linear and log binomial regression models were fitted to estimate risk ratios (RR) and 95% 
confidence intervals (CI) for estimated fetal and newborn anthropometrics, before and after 
adjusting for potential confounders. Based on previous studies, the potential modifying 
effects of maternal BMI and primagravida status were evaluated [11].  A p-value of <0.15 for 
the interaction term was selected to indicate statistical significance.  Additional potential 
confounders evaluated were socio-demographic status (household expenditures, 
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educational level, maternal age), and bednet use. A backward elimination strategy was used 
to fit the multivariate models for birth weight.  Ultrasound measurements were stratified by 3-
week gestational age groups (18-35 weeks gestation) and compared malaria infected to not 
infected women. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4 Directed Acyclic graph: Malaria and birth weight 
 
Data analyses for Aim II. Maternal malaria, hookworm and anemia 
 
This analysis explored the associations of malaria and hookworm at the first 
antenatal care visit with moderate/severe maternal anemia, considering other parasitic 
infections associated with maternal anemia, maternal under-nutrition (as measured by low 
BMI), and other potential confounders (identified through literature review and directed 
acyclic graph, 3-5).  
 
Malaria in pregnancy 
Demographic status 
Nutrition (body mass 
index) 
Primigravidity 
Young maternal age 
Treatment (bednet use) 
Birth Weight 
Gestational age (PTB) 
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Primigravidity, maternal age, maternal education, bednet use, and marital status 
were evaluated as potential confounders, based on previous research [See Chapter 2] [92]. 
Confounders with a change estimate >10% were kept in the final log-risk model to evaluate 
the contribution of hookworm, malaria, and other infections to maternal anemia. 
Furthermore, maternal anemia in pregnancy was adjusted for gestational age at 
measurement. The estimated risk ratios for maternal anemia for each infection were 
estimated, with and without the potential confounders. Finally, a log-risk model was 
developed to estimate the association of the common infections (P. falciparum malaria, 
hookworm, schistosomiasis, T. trichuria) and moderate/severe maternal anemia. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5. Directed acyclic graph: Infection in pregnancy and anemia  
 
Malaria in pregnancy 
Demographic status 
Under-nutrition (BMI) 
Gestational age 
Bednet use 
Maternal anemia Hookworm 
Schistosomiasis and 
other infections 
Young maternal age 
Gravidity 
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3.4 Sensitivity analyses for missing birth outcome data 
 
For the study, as described, women who had term births (n = 501/799 or 63% of 
those enrolled at ANC) were subsequently enrolled for the parent study, whose goal was to 
assess effect of fetal immunity.  Thus, for the present study, the association of malaria and 
reduced birth weight associated with preterm birth was unable to be assessed, only birth 
weight associated with intra-uterine growth restriction among term births. Since there were a 
significant proportion (n=298 or 37%) of women enrolled at antenatal care but whose infants 
were not enrolled at delivery for various reasons (including delivering outside the catchment 
hospital, preterm birth, stillbirth, voluntary withdrawal or other unknown reasons) (shown in 
Figure 3-3), we examined the demographic variables at antenatal care for those who 
delivered vs. who did not deliver at the study hospital for demographic variables with key 
study variables displayed (Table 3-1).  Of those who were PCR- malaria-positive at ANC, 
38% (n=23) had missing delivery data, while for those who were PCR-malaria negative at 
ANC, 38% (n=275) also had missing data at delivery.  While there were slightly reduced 
rates of anemia at ANC (p<0.05), other demographic variables did not differ significantly 
between those women with outcomes obtained at delivery at the study hospital compared to 
those without data at delivery available. One important limitation is that the specific reason 
for lack of delivery outcomes (e.g., preterm birth, fetal death, lost to follow-up) was 
unavailable. 
 
    Additionally, a sensitivity analyses was conducted to examine the possible range of 
differences in mean birth weight for those with PCR-malaria vs. no PCR-malaria at antenatal 
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care, but with missing birth weight.  As a first step, the median, 10th, 25th and 75th percentiles 
birth weights were calculated for those with birth weight measurements available, stratified 
by PCR-malaria status as follows:   
• PCR-malaria positive:10th percentile 2300 g; 25th 2600 g; 75th 3250 
• PCR-malaria negative: 10th percentile 2400 g; 25th percentile 2750 g; 75th 3750  
 
    Second, the sensitivity analyses were conducted to assess the impact of missing data 
for the 38% without birth weight (38% of both PCR-positive and PCR-negative groups were 
missing) under different assumptions for the value of missing birth weight to evaluate the 
potential ranges of birth weight differences. As shown in Table 3-8, at the most extreme, 
assuming all missing PCR-positive birth weights were at the 10th%ile and PCR-negative 
birth weights were at the 75%ile, there would have been mean difference of -907 g (95% CI 
-983, -831 g). Similarly, the opposite extreme, finds a similar magnitude of difference with 
malaria-positive women having approximately an 856 g mean higher birth weight. If both 
groups with missing birth weight data had had the actual median birth weights for PCR-
positive and negative, PCR-malaria exposure would have had a non-significant impact on 
birth weight, mean difference 32 g (95% CI -34, 98 g), as was the actual scenario (described 
in subsequent chapters).  
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Table 3-1 Demographics of women who delivered at the study hospital vs. birth outcome not 
recorded 
 Delivered at study hospital 
N (%) 
Delivered elsewhere 
N (%) 
Chi2 p-value 
Maternal Age   0.08 
  < 20 yrs 171 (38.3) 141 (37.1)  
   >20 yrs 276 (61.7) 239 (62.9)  
Gravidity   0.1 
  Primigravida 118 (26.5) 81 (21.5)  
  Multigravida 296 (78.5) 239 (62.9)  
Used bednet past 3 mos   0.4 
  No 115 (26.0) 103 (27.1)  
  Yes 327 (27.0) 277 (72.9)  
Moderate/severe Anemia   0.01 
  No 286 (74.9) 237 (71.0)  
  Yes 96 (25.1) 97 (29.0)  
PCR-malaria   0.1 
  No 45 (10.1) 42 (11.3)  
  Yes 398 (89.9) 328 (88.7)  
Hookworm   0.4 
  No 257 (76.5) 242 (75.4)  
  Yes 79 (23.5) 79 (24.6)  
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Table 3-2 Comparison of CWRU-PCR to UNC-PCR for P. falciparum malaria parasitemia 
detection 
 UNC- Positive UNC-Negative Total 
CWRU – Positive 7 1 8 
CWRU – Negative 2 15 18 
Total 9 16 25 
 
Table 3-3. Sensitivity and specificity of microscopy (MS) compared to CWRU PCR for P. 
falciparum malaria parasitemia detection  
 
Pf-MS Positive Pf-MS Negative Total 
Pf- PCR Positive 13 46 59 
Pf- PCR Negative 5 368 373 
Total 18 414 432 
 
Table 3-4 Maternal Body-Mass-Index (BMI) by Gestational Age (GA) at Measurement 
GA, 
weeks 
N (%) BMI, Median BMI, 10th percentile BMI, 90th 
percentile 
18-20 64 (9) 24.3 19.5 30.1 
21-23 92 (13) 23.9 20.4 28.2 
24-26 135 (19) 24.9 20.7 29.9 
27-29 182 (26) 24.5 20.7 29.7 
30-32 140 (20) 25.3 20.8 30.2 
33-35 89 (13) 24.4 21.3 31.4 
 
Table 3-5. Relative risk of low BMI by infection (RR and 95% CI)  
 Low BMI, RR (95% CI) P-value 
PCR-Malaria 0.8 (0.4, 1.7) 0.4 
Microscopy-malaria 1.5 (0.5, 4.3) 0.5 
Hookworm 0.8 (0.5, 1.4) 0.5 
Hookworm >100 eggs/g 0.7 (0.9, 5.7) 0.7 
Schistosomiasis 1.2 (0.8, 1.9) 0.4 
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Table 3-6. Summary of key exposure and outcome study variables  
Variable Description Defined for study 
Antenatal Care 
P. falciparum malaria PCR-positive  Dichotomous 
Hookworm Positive/negative -  
 
Continuous (eggs/g) 
 
Dichotomous  
 
Burden - dichotomous  
(> 100 eggs/mL) 
 
Other parasitic 
infection (T. trichuria, 
S. stercoralis, A. 
lumbricoides) 
Positive/negative -  
 
Continuous (eggs/g) 
Dichotomous  
 
Burden - dichotomous (> 100 
eggs/g) 
 
Schistosomiasis 
(S.haematobium) 
 
Positive/negative -  
 
Continuous (egg/mL) 
 
 
Dichotomous 
 
Burden - dichotomous (> 50 
eggs/mL) 
 
Table 3-5 continued   
Body-mass-index Kg/m2 as continuous variable 
 
Low BMI defined as lowest 
10%ile for GA       
  
Ultrasound 
measurements 
Biparietal diameter, femur length, 
head circumference, estimated fetal 
weight 
 
Continuous  
Maternal anemia Hemoglobin (Hg) - g/dL 
  
Anemia – Hb < 11.0 g/dL 
Moderate/severe< 9.0 g/dL 
Delivery 
P. falciparum malaria PCR-positive Dichotomous 
Hookworm Positive/negative -  
 
Burden of infection (eggs/mL) 
 
Dichotomous  
 
Moderate burden - dichotomous 
(> 100 eggs/mL) 
Schistosomiasis Positive/negative -  
Burden of infection (egg/mL) 
 
Dichotomous 
Birth weight Continuous (grams) Continuous 
Anthropometrics Length, head circumference Continuous  
Maternal anemia Hemoglobin (Hg) - g/dL 
  
Anemia: Hb < 11.0 g/dL 
Moderate/severe: Hb < 9.0 g/dL 
 
Fetal anemia Cord hemoglobin (Hg) - g/dL 
  
Anemia: Hb < 12.5 g/dL 
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Table 3-7. Difference in birth weight (Mean, g, and 95% CI) with imputed missing birth 
weights using available birth weights, by PCR negative vs. PCR positive malaria*  
 Assumptions about missing birthweight (BWT) for PCR-malaria negative 
Mean difference, 95% CI 
Assumptions 
about BWT for 
PCR-malaria 
positive 
10th percentile 25th percentile 
malaria-
negative BWT 
Median malaria-
negative BWT 
75th percentile 
malaria-negative 
BWT 
10th percentile  31 (-34, 97) -428 (-486, -371) -668 (-734, -602) -907 (-983, -831) 
25th percentile  357 (307, 407) -128 (-186, -71) -368 (-433, -302) -607 (-683, -531) 
Median  606 (611, 718) 271 (214, 329) 32 (-34, 98) -207 (-283, -131) 
75th percentile 856 (806, 906) 665 (611, 718) 281 (216, 318) 43 (-34, 118) 
*values imputed for those with missing birthweight (n= 303) based on malaria status at ANC  
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CHAPTER FOUR 
 
P. FALCIPARUM MALARIA AND BIRTHWEIGHT 
 
Introduction 
 
Malaria in pregnancy causes low birth weight, a major contributor to neonatal 
mortality and morbidity worldwide [1,2,93,94].  In Sub-Saharan Africa, where malaria is 
endemic, malaria in pregnancy may contribute to 25% of low birth weight [95].  Risk of 
decreased birth weight is generally highest among primigravida women, who may 
experience more severe clinical illness associated with malaria infection [1,2]. Additionally, 
while maternal under-nutrition as determined by low body-mass index (BMI) has been 
associated with low birth weight [96,97], a recent study suggested an interaction between 
maternal under-nutrition and malaria [60]. The study, conducted in the Democratic Republic 
of Congo (DRC), found that among those women with malaria during pregnancy, intra-
uterine growth restriction (IUGR) and birth weight were significantly reduced among women 
with under-nutrition [60].  
 
In addition to the relation between maternal characteristics and malaria on birth 
weight, recent studies point to a role of the timing of malaria infection [13,23,60,98]. 
Although few studies have evaluated early infection and birth weight, some have suggested 
that first or second trimester infection increases risk of low birth weight compared to later 
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infection [98]. However, other studies have found malaria infection late in pregnancy, when 
fetal weight gain is most rapid, correlated with decreased birth weight [13,23].   
 
Studies of malaria in pregnancy utilizing ultrasound, a method to establish 
gestational age and fetal growth, have been limited [60,99-101]. In addition to evaluation of 
fetal growth, ultrasound assesses uterine and umbilical blood flow, both of which may be 
impaired by malaria in pregnancy [100]. With limited availability of routine ultrasound in Sub-
Saharan Africa, few reports have described fetal growth and impairment associated with 
malaria by ultrasound.  One study of 3,779 pregnant women from the Thai-Burmese border 
found that early malaria infection (<24 weeks) was associated with decreased biparietal 
diameter (BPD).[100]  Another recent study in Tanzania, found that early malaria infection 
was associated with reduced third trimester fetal growth [101]. Additionally, in DRC, 
ultrasound evaluations established IUGR among women with malaria [60] and significantly 
increased uterine and umbilical artery resistance among malaria-positive compared to 
malaria-negative pregnant women [99]. Umbilical artery resistance has been associated with 
impaired fetal growth and intra-uterine growth restriction [102]. 
 
Given the adverse birth outcomes associated with malaria and the effective 
treatment now available, in 2004 the World Health Organization (WHO) recommended 
intermittent preventive treatment with two doses of SP (IPTp-SP) beginning the second 
trimester for pregnant women residing in malaria-endemic areas [5]; more recent WHO 
guidelines recommend monthly SP treatment [42]. With the increased SP availability, many 
countries in Sub-Saharan Africa have implemented programs based on the IPTp-SP 
strategy and evaluation efforts have been undertaken [26, 27,103]. However, a better 
understanding of factors related to the impact of malaria on birth outcomes is needed to 
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optimize public health programs. We therefore sought to explore the impact of malaria in 
pregnancy on fetal growth and newborn outcomes among a cohort of women enrolled in an 
IPTp-SP treatment program in a malaria-endemic region.  
 
Materials and methods 
 
Study population and recruitment 
 
From 2006 to 2009, the study team recruited pregnant women who attended 
antenatal care (ANC) at Msambweni District Hospital, Msambweni, Coast Province, Kenya, 
a rural area where malaria is endemic [67].  Per Kenya Ministry of Health national policy, 
women received IPTp beginning in the second trimester as well as iron, folic acid, and bed 
nets as part of routine care.  At the first ANC visit, consented HIV-negative women were 
tested for peripheral malaria, demographic information was obtained, and a physical 
examination and an ultrasound examination were performed. Pregnant women with known 
medical disorders contributing to fetal growth restriction, placental dysfunction, twin 
pregnancy, and prematurity were excluded.  Participating women who delivered a term, live 
infant at the Msambweni District Hospital had maternal venous, placental and cord blood 
tested for hemoglobin level and malaria parasites.  Neonatal anthropometric measurements 
were obtained within 24 hours of delivery including birth weight, head circumference and 
length.   All women provided written, informed consent. The study, part of a larger study on 
fetal immunity to malaria, was approved by the Institutional Review Boards at Kenya Medical 
Research Institute, Case Western Reserve University, and the University of North Carolina 
Chapel Hill.  
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Measurements 
 
All anthropometric measurements were obtained by trained study staff.  Maternal 
BMI was calculated based on maternal weight and height obtained at the first antenatal care 
visit (kg/m3). Because a pre-pregnancy BMI was unavailable, to explore the potential effects 
of under-nutrition, BMI less than the 10 percentile for the gestational age at ANC was 
calculated and defined as low BMI. Ponderal index (PI), the ratio of infant length to weight, 
was also calculated with PI <2.32 defined as asymmetrical growth.  
 
Ultrasound examinations were performed using a SonoSite 180 Plus ultrasound 
machine (SonoSite FujiFilm, Bothell, WA).  Fetal biometry was performed according to 
standard techniques for determination of fetal gestational age and weight.  Right and left 
uterine arteries were interrogated using standard techniques.  Notching of uterine arteries 
was noted in pregnancies greater than 25 weeks gestation.   Umbilical artery interrogation 
was performed on a free flowing segment of umbilical cord.   
 
Presence of malaria parasitaemia was determined by polymerase chain reaction 
(PCR)-ligase detection reaction/fluorescent microsphere assay as previously described [86]. 
For purposes of this study, analyses of malaria were restricted to P. falciparum, the species 
most commonly associated with adverse birth outcomes [2].  
 
Data analyses 
All analyses were performed in SAS version 9.3 (SAS Institute, Cary, NC, USA).  
Descriptive analyses were performed with chi-square and t-tests to evaluate differences in 
estimates. Linear and log binomial regression models were fitted to estimate risk ratios (RR) 
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and 95% confidence intervals (CI) for estimated fetal and newborn anthropometrics, before 
and after adjusting for potential confounders. Based on previous studies, the potential 
modifying effects of maternal BMI and primagravida status were evaluated.  A p-value of 
<0.15 for the interaction term was selected to indicate statistical significance.  Additional 
potential confounders evaluated were socio-demographic status (household expenditures, 
educational level, maternal age), and bednet use. A backward elimination strategy was used 
to fit the multivariate models for birth weight.  Ultrasound measurements were stratified by 3-
week gestational age groups (18-35 weeks gestation) and compared malaria infected to not 
infected women. 
 
Results 
 
 
Of the 813 women screened at antenatal care (ANC), 799 provided initial 
demographic information and were tested for malaria; 676 had an ultrasound examination at 
the first ANC visit between 18 and 35 weeks and were included in analyses of fetal 
measurements.  Of these, 463 delivered a term, singleton, live birth in the study hospital.  
 
The median gestational age at the first visit was 27 weeks (IQR 24, 31 weeks).  
Demographic characteristics and relative risk analyses are presented in Table 4-1 for 
women with and without P. falciparum infection at their first ANC visit. Overall, 87 (11%) of 
women tested positive for P. falciparum malaria by PCR. In unadjusted analyses, women 
who were <20 years of age and primigravida had a higher risk of P. falciparum (RR 2.10 
95% CI 1.38, 3.18 and RR 1.68 95% CI 1.11, 2.54, respectively), while the socio-economic 
status (as measured by household expenditures), marital status, and educational status 
were not significantly associated with malaria. Finally, women who were not using bednets 
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prior to ANC were more likely to be malaria positive (RR 1.71, 95% CI 1.14, 2.55).  Women 
who did not have malaria treatment prior to ANC had a relative risk of 1.68 (95% CI 0.76, 
3.74) of being malaria positive at the first ANC visit.  Women with moderate or severe 
anemia (hemoglobin <9 g/dl) had a higher relative risk of exposure to malaria.  The median 
BMI was 24.2 (IQR 22.2, 26.9) and similar for the malaria-positive women (23.9, IQR 22.1, 
26.0). Finally, we examined clinical symptoms of febrile illness and only 4 of the women who 
were malaria-positive had illness (data not shown).   
 
Analyses adjusted for parity and stratified by gestational age to examine the 
association of concurrent P. falciparum status and fetal growth estimated by ultrasound are 
reported in Table 4-2.  The mean adjusted estimated fetal weight measurements were 
generally lower for fetuses exposed to P. falciparum positive compared to negative mothers; 
however, except at 30-32 weeks’ gestation, these differences did not reach statistical 
significance. At 30-32 weeks, the fetal weight, head and abdominal circumference were 
significantly lower (p<0.05) for P. falciparum positive mothers, while femur length 
measurements were similar between the groups across all gestational ages (Table 4-5, 
supplemental tables).   
 
Additionally, we examined measures of uteroplacental blood flow for malaria-positive 
vs. negative women, adjusted for primigravid status.  Umbilical artery resistance index (RI) 
was higher among the P. falciparum positive, compared to negative fetuses, with statistically 
difference measurements (p<0.05) detected at ultrasound available at or prior to 26 weeks 
gestation (Table 4-2). No statistically significant differences in umbilical artery pulsatility 
index (PI) or systolic/diastolic (S/D) ratio were found nor were statistically significant 
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differences in uterine artery notching, RI, PI, or S/D ratio between the groups found (data 
not shown). 
 
Next, we examined birth anthropometrics and hemoglobin levels for live, singletons. 
Compared to women whose births were excluded (due to delivery outside the study hospital, 
voluntary discontinuance of study participation, lost to follow up, premature delivery, or non-
collection of samples and measurements), women whose births were included were 
comparable on incidence of malaria, education level, gravidity, age, and household 
expenditures to those whose births were excluded from the study, and maternal severe or 
moderate anemia. However, enrolled women who delivered a live birth in the study hospital 
were significantly less likely to have a low BMI percentile (p<0.05), compared to women 
whose birth data were not available.  
 
Of women with a live, term birth at the study hospital (n=463), 8% were delivered by 
cesarean section. Overall, 54.7% of the neonates were male and the median gestational 
age was 39.0 weeks (IQR, 37.9, 39.9), neither of which differed by malaria status. In a 
multivariate regression analyses, maternal factors which remained significantly associated 
(at p<0.05) with reduced birth weight were primigravidity, young maternal age (<20 years), 
and low BMI.  Because of the collinearity between primigravidity and young age, only parity 
remained in the initial model. Anthropometric measurements for newborns of women with P. 
falciparum detected at the first ANC visit or at delivery were similar to those without P. 
falciparum in both adjusted and unadjusted analyses (Table 4-3).  While the incidence of 
malaria at delivery was slightly lower (10%) than at first ANC visit (11%), women who were 
malaria-positive at first ANC visit were at higher risk of having any malaria at delivery 
(placenta, cord or peripheral samples) (aRR 2.1, 95% CI 1.0, 4.4, p = 0.05). 
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Finally, we examined the role of maternal BMI (< 10th percentile, adjusted for 
gestational age) and malaria. Low BMI had a significant interaction (p=0.06) with P. 
falciparum status and thus an interaction term was included in the linear regression model to 
evaluate the association of malaria with birth weight.  In the model for term births, adjusted 
for gravidity, malaria was not significantly associated with lower birth weights among women 
with normal BMI, but was associated with a decreased birth weight among women with low 
BMI (-370 g, 95% CI –728, -12, p=0.04) (Table 4-4).   
 
Discussion 
 
 
Approximately 11% of women were positive for malaria at ANC and, similar to 
previous studies, risk of malaria was associated with primigravida status and younger 
maternal age [1].  We also found a significantly higher risk of malaria among women who did 
not use bednets.  In the region, distribution of free insecticide-treated bednets in addition to 
the IPTp-SP program were active during the study period and likely contributed to relatively 
low burden of malaria infection, compared to earlier studies.  In contrast, in a study from the 
same region of Kenya conducted from 2000 through 2005 - prior to widespread adoption of 
the WHO IPTp-SP guidelines - 42% of women were malaria-positive at time of delivery [67]. 
 
This is one of the few studies to evaluate concurrent malaria with ultrasound 
measurements of fetal growth and uteroplacental blood flow.  While modest, the estimated 
fetal anthropometrics suggested potential reduced growth associated with malaria, 
especially late in the second trimester when fetal growth is most rapid.  There was also a 
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trend for higher umbilical artery RI among women with malaria, consistent with a recent 
study, which found that early malaria parasitaemia was associated with increased umbilical 
artery RI among primigravida, but not multigravida women [99].  Increased umbilical artery 
RI has been associated with intrauterine growth restriction in previous studies [10]. 
 
In this population treated with IPTp-SP, malaria detected by PCR at ANC did not 
have a significant impact on birth weight or other anthropometric measurements in this 
cohort of live term births.  However among those women with the lowest BMI, malaria was 
significantly associated with reduced birth weight.  While factors leading to low BMI are 
complex, in this study, low BMI appeared to be the maternal factor most highly associated 
with reduced birth weight.  A previous study conducted in the DRC found a similar trend, 
with significant impact of malaria primarily among those with indicators of under-nutrition 
[60].   
 
The widespread distribution of bednets, even prior to enrollment which was 
associated with significant decreased risk of malaria at ANC as well as the provision of 
IPTp-SP likely contributed to decreased risk for repeat or severe malaria infection, 
consistent with previous studies [41]. Both of these confirm the important role of treatment 
programs in reducing the prevalence of malaria in pregnancy.  
 
A limitation of this study was that the women who were seen at ANC but 
subsequently delivered outside the study hospital or who did not deliver a live, term birth 
were excluded. Thus, we were unable to determine the contribution of malaria to preterm 
birth or other potentially adverse pregnancy outcomes. While the women excluded had 
higher rates of low BMI, they did have comparable malaria rates to those with birth 
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outcomes.  Another consideration is that we evaluated malaria detected by PCR, rather than 
women with febrile illness or repeated infections, and thus these findings are limited to the 
impact of potential modest malaria exposure on birth outcomes.  However, even among 
women who received among the best care and had optimal outcomes, malaria and under-
nutrition was found to be associated with reduced birth weight. 
 
Conclusions 
 
Risk of malaria at delivery was associated with presence of malaria at first ANC visit, 
which was reduced among those using bednets. We found that malaria detected by PCR at 
ANC was associated with only a modest reduction in fetal growth that with IPTp and by term 
birth, no difference in birth weights was found.  This suggests that with good preventive 
care, the impact of exposure to malaria on fetal and newborn growth may be minimized. 
However, maternal BMI was highly associated with birth weight, and among women with 
lowest BMI, the impact of malaria was more pronounced. Additional research and programs 
to improve maternal nutritional health may be important to important to further improving 
birth outcomes in low-resource settings.   Taken together, these results suggest that mild 
malaria infection detected at first ANC, among women given IPTp-SP and who delivered at 
a study hospital, was not associated with significant adverse outcomes among term births.     
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Table 4-1. Maternal characteristics and relative risk (95% CI) for P. falciparum malaria at 
first antenatal care (ANC) visit, Kenya cohort, 2006–2009 
 Total 
N* (%) 
P falciparum 
n (%) 
RR (95% CI) † 
Maternal Age    
   20-45 658 (82.3) 60 (9.1) Referent 
   < 20 141 (17.7) 27 (19.2) 2.10 (1.38, 3.18) 
    
Formal education 
   
    No education 163 (20.6) 17 (10.4) Referent 
    Primary education 526 (66.4) 58 (11.0) 1.05 (0.63, 1,76) 
    Secondary/higher level 103 (13.0) 11 (10.7) 1.11 (0.40, 3.11) 
 
   
Low household income 
   
   No 299 (36.8) 27 (9.0) Referent 
   Yes 514 (63.2) 60 (11.7) 1.31 (0.91, 1.88) 
 
   
Marital status 
   
   Married/partner 698 (87.9) 72 (10.3) Referent 
   Widow/divorced/single 96 (12.1) 14 (14.6) 1.41 (0.83, 2.40) 
 
   
Gravidity 
   
   Multigravida  601 (75.9) 56 (9.3) Referent 
   Primigravida 191 (24.1) 30 (15.7) 1.68 (1.11, 2.54) 
 
   
Bednet use last 3 mos 
   
    Yes 583 (73.6) 54 (9.3) Referent 
    No 209 (26.4) 33 (15.8) 1.71 (1.14, 2.55) 
 
   
Malaria treatment last 3 mos 
   
     Yes 88 (11.1) 6 (6.9) Referent 
     No 706 (88.9) 81 (11.5) 1.68 (0.76, 3.74) 
 
   
Maternal anemia 
   
   Hemoglobin > 9 506 (73.3) 38 (7.5) Referent 
   Hemoglobin < 9 184 (26.7) 21 (11.4) 1.38 (0.95, 1.99) 
 
   
Body mass index, median (IQR) 24.2 (22.2, 
26.9) 
23.9 (22.1, 26.0) -- 
*Differences in numbers due to missing data  
†Unadjusted risk ratio (RR) and 95% confidence interval  (CI) 
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Table 4-2. Estimated fetal weight and umbilical resistance index stratified by gestational age 
(GA) and concurrent P. falciparum at first antenatal care visit, Kenya cohort, 2006–2009. 
 
 Estimated Fetal Weight* Umbilical Resistance Index (RI) 
GA at 
measure 
Concurrent  
malaria† (N) 
Mean‡, 
grams 
Mean 
Difference 
(95% CI) ‡ 
p-value Mean‡ 
RI 
Mean Difference 
(95% CI) ‡ 
p-
value 
18-20 wks Positive (N=6) 277 -37 (-86, 15) 0.15 0.82 0.042  
(0.0098, 074) 
0.01 
 Negative (N=45) 314   0.78   
21-23 wks Positive (N=8 ) 522 16 (-45, 78) 0.61 0.78 0.025 (-0.044, 
0.093)  
0.5 
 Negative (N=85) 506   0.75   
24-26 wks Positive (N=16 ) 729 -23 (-84, 38) 0.46 0.75 0.031 (-0.0016, 
0.064)  
0.06 
 
Negative 
(N=118 ) 
815   0.72   
27-29 wks Positive (N=25 ) 1190 -33 (-94, 27) 0.28 0.70 0.011 (-0.017, 
0.042) 
0.3 
 
Negative 
(N=160 ) 
1223   0.69   
30-32 wks Positive (N=12 ) 1683 -126 (-237, -
14) 
0.03 0.67 0.015 (-
0.022,0.053) 
0.4 
 
Negative 
(N=121) 
1809   0.66   
33-35 wks Positive (N=7 ) 2344 -16 (-172, 
141) 
0.84 0.68 0.029 (-
0.022,0.081) 
0.4 
 Negative (N=73) 2359   0.66   
*Hadlock’s formula for estimation of fetal weight, grams (27)      †P falciparum malaria at 
antenatal care  
 ‡Estimated mean and mean differences, adjusted for primagravida status 
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Table 4-3. Birth outcomes and malaria at delivery by P. falciparum malaria at antenatal care, 
Kenya cohort, 2006–2009  
 
     
 Malaria 
status* (N**) 
Adjuste
d 
Mean† 
Mean Difference  
(95% CI) † 
p-value 
Gestational age (wks)     
 Positive 
(N=43) 
38.8 -0.06 (-1.2, 0.9) 0.8 
 Negative 
(N=388) 
38.9   
Birth weight (g)     
 Positive 
(N=43) 
3072 -5 (-131, 121) 0.9 
 Negative 
(N=422) 
3077   
Infant length (cm)     
 Positive 
(N=43) 
49.0 0.2 (-0.9, 1.2) 0.7 
 Negative 
(N=417) 
48.8   
Head circumference 
(cm) 
    
 Positive 
(N=43) 
34.5 0.05 (-0.7, 0.8) 0.9 
 Negative 
(N=417) 
34.4   
* P. falciparum malaria status at antenatal care visit  
† Mean and mean difference from linear regression model, adjusted for primagravida 
status 
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Table 4-3. Birth outcomes and malaria at delivery, continued 
 
 N** (%) aRR (95% CI) ‡ p-value 
Ponderal index<2.32 
(Kg/cm3) 
 
   
 Positive 
(N=43) 
7 (16) 0.96 (0.47, 1.95) 0.9 
Negative 
(N=422) 
69 (16) 1.0  
Cord hemoglobin  
<12.5 (g/dl) 
    
 Positive 
(N=42) 
8 (20) 1.15 (0.57, 2.21) 0.7 
 Negative 
(N=365) 
62 (18) 1.0  
Malaria at delivery§ (%)     
 Positive 
(N=42) 
7 (18) 2.1 (1.0, 4.4) 0.05 
 Negative 
(N=365) 
29 (8) 1.0  
* P. falciparum malaria status at antenatal care visit   **Numbers vary due to missing data 
† Mean and mean difference from linear regression model, adjusted for primagravida status 
‡ Risk ratio and 95% confidence interval from log binomial risk model, adjusted for 
primagravida status 
§ P. falciparum malaria at delivery defined as cord, placenta and maternal peripheral 
determined by PCR  
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Table 4-4. Associations between birth anthropometrics and maternal malaria, stratified by 
maternal BMI, Kenya cohort, 2006–2009 
 Malaria status* (N) Adjusted 
Mean † 
Mean Difference 
(95% CI) † 
p-value 
Birth weight, g     
   BMI < 10%ile Positive (N = 8) 2658 -370 (-728, -12) 0.04 
 Negative (N=26) 3028   
   BMI > 10%ile Positive (N=47) 3161 75 (-91, 241)  0.4 
 Negative (N=265) 3087   
Birth length, cm     
   BMI < 10%ile Positive (N = 8) 48.1 -1.3 (-3.6, 2.4) 0.4 
 Negative (N=26) 49.0   
   BMI > 10%ile Positive (N=47) 49.1 0.7 (-0.9, 1.4) 0.4 
 Negative (N=265) 48.8   
Head circumference, cm      
   BMI < 10%ile Positive (N = 8) 33.7 -0.8 (-3.1, 1.5)  0.4 
 Negative (N=26) 34.5   
   BMI > 10%ile Positive (N=47) 34.7 0.2 (-0.9, 1.1)  0.8 
 Negative (N=265) 34.5   
 
*P falciparum at first antenatal care visit  
†Adjusted for primigravida status 
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Table 4-5. Supplementary ultrasound measurements, Kenya study, 2006-2009. 
  Head circumference (cm) Abdominal circumference (AC) 
  Adjusted±        
GA at 
measure 
Concurrent  
malaria† 
(N) 
Adjusted 
Mean± 
Mean 
Difference 
95% CI of 
difference 
p-value Adjusted± 
Mean 
Mean 
Difference 
95% CI of 
difference 
p-value 
18-20 
wks 
Present 
(N=6) 
15.97 -0.65 -2.62, 1.31 0.5 13.77 -0.96 -1.9, 0.0 0.08 
 Absent 
(N=45) 
16.62    14.73    
21-23 
wks 
Present 
(N=8 ) 
20.21 0.06 -0.79, 0.092 0.9 17.69 0.19 -0.6, 1.2 0.7 
 Absent 
(N=85 ) 
20.15    17.51    
24-26 
wks 
Present 
(N=16 ) 
23.24 -0.4 -1.00, 0.200  20.60 -0.28 -0.9, 0.3 0.4 
 Absent 
(N=118 ) 
23.64    20.88    
27-29 
wks 
Present 
(N=25 ) 
 
26.35 -0.11 -0.5, 0.3 0.6 23.75 -0.30 -1.0, 0.5  0.5 
 Absent 
(N=160 ) 
26.46    24.04    
30-32 
wks 
Present 
(N=12 ) 
28.58 -0.69 -1.21, -0.16 0.01 26.97 -0.69 -1.4, 0.06 0.06 
 Absent 
(N=121 ) 
29.27    27.66    
33-35 
wks 
Present 
(N=7 ) 
31.04 -0.09 -0.65, 0.48 0.8 29.89 -0.15 -1.4, 1.1 0.8 
 Absent 
(N=73) 
31.13    30.04    
†P falciparum malaria at antenatal care  
 ‡Estimated mean and mean differences, adjusted for primagravida status 
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  Biparietal diameter (cm) Femur length (cm) 
GA at 
measure 
Concurrent  
malaria† 
(N) 
Mean± Mean 
Differenc
e 
95% CI of 
difference 
p-value Mean± Mean 
Difference 
95% CI of 
difference 
P-value 
18-20 
wks 
Positive 
(N=6) 
4.24 -0.29  0.1 2.95 -0.50 -2.06, 1.06 0.5 
 Negative 
(N=45) 
4.53    3.44    
21-23 
wks 
Positive 
(N=8 ) 
5.42 0.048 -0.21, 0.30 0.7 3.96 0.09 -0.11, 0.29 0.4 
 Negative 
(N=85 ) 
5.37    3.88    
24-26 
wks 
Positive 
(N=16 ) 
6.22 -0.05 -0.20, 0.11 0.5 4.76 -0.27 -1.45, 0.91 0.6 
 Negative 
(N=118 ) 
6.27    5.03    
27-29 
wks 
Postive 
(N=25 ) 
7.06 0.003  0.96 5.29 -0.14 -0.77, 0.48 0.6 
 Negative 
(N=160 ) 
7.05    5.44    
30-32 
wks 
Positive 
(N=12 ) 
7.63 -0.23 -0.40, -0.05 0.01 5.86 -0.11 -0.31, 0.10 0.3 
 Negative 
(N=121 ) 
7.86    5.97    
33-35 
wks 
Postive  
(N=7 ) 
8.32 -0.15 -0.32, 0.03 0.09 6.57 0.03 -0.22, 0.27 0.8 
 Negative 
(N=73) 
8.47    6.54    
†P falciparum malaria at antenatal care  
 ‡Estimated mean and mean differences, adjusted for primagravida status 
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CHAPTER FIVE 
MATERNAL AND NEONATAL ANEMIA 
 
Introduction 
 
Anemia affects nearly 25% of all pregnancies worldwide and more than 40% of those 
in Sub-Saharan Africa [104]. Defined as hemoglobin <11 g/dL, anemia in pregnancy 
contributes to maternal morbidities and increased risk for mortality associated with 
conditions such as post-partum hemorrhage [105-108].  Maternal anemia has also been 
associated with fetal anemia, which contributes to infant anemia as well as long-term 
childhood morbidities, including impaired neurodevelopmental outcomes [45, 109-112]. 
 
Although anemia is multi-factorial, poor nutrition and infection are common causes. 
In Sub-Saharan Africa, soil-transmitted helminthes (STH) including hookworm, urogenital 
schistosomiasis, and other parasitic infections such as malaria contribute to the high anemia 
rates in women and young children [113-120]. Infection prevalence of up to 50% has been 
documented in some regions in Sub-Saharan Africa [121]. Estimates suggest that more than 
25% of pregnant women are infected with hookworm, which causes intestinal bleeding and 
blood loss, and has been most commonly associated with anemia [104,122-124].  In a study 
of parasitic infection in pregnancy conducted in coastal Kenya from 2000 to 2005, about 
32% of women were infected with hookworm, 31% with urogenital schistosomiasis (S. 
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haematobium), and almost 43% with malaria (P. falciparum), while more than 46% of 
women were co-infected [67]. 
 
Parasitic infections, including hookworm, may be evaluated by intensity of infection, 
as measured by the concentration of eggs in the stool. While most morbidity has been seen 
with high intensity infections, in populations with low iron stores, even low-intensity 
hookworm infection has been associated with morbidities [125,126]. In addition to 
hookworm, P. falciparum malaria has been shown to increase risk for moderate and severe 
maternal anemia [113-119]. While urogenital schistosomiasis causes adverse health 
outcomes including anemia, its association with maternal anemia has been less clearly 
established [127,128].  Finally, poor nutrition, which contributes to inadequate intake of iron, 
folate, and other micronutrients, is common in the geographic areas where these parasitic 
infections are prevalent, and may have an important role in the relationship of infections and 
anemia [96,129-132].  
 
Many studies have focused on the effects of a single infectious agent on pregnancy 
outcome and maternal anemia, although a few studies have attempted to understand the 
relative effects of multiple agents with conflicting results [67,131]. Fetal anemia has been 
documented in association with maternal anemia, with rates of 10% to 23% reported in 
recent studies in Malawi [45,108,109], but its association with infection is less well 
understood.   
 
With preventative treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) as 
recommended by the World Health Organization (WHO) in 2004, rates of malaria in 
pregnancy have decreased [41,42,133]. Thus, other causes of maternal anemia and poor 
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birth outcomes have become increasingly important.  Recent trials show that presumptive 
hookworm treatment reduces the infection rates in pregnancy, although the impact on 
pregnancy outcomes such as maternal anemia has varied [134-137]. Where hookworm 
infection is endemic, the WHO recommends provision of antihelminthic treatment (e.g., 
albendazole or other treatments safe during pregnancy) in the second trimester [137]. 
Furthermore, safe, effective treatment is available to treat urogenital schistosomiasis during 
pregnancy and endorsed by the WHO [139]. However, for various reasons, the WHO 
recommendations for hookworm and urogenital schistosomiasis treatment during pregnancy 
have not been widely implemented [140].  In this study, we sought to ascertain the 
contributions of parasitic infection among a cohort of pregnant women in coastal Kenya to 
maternal and fetal anemia. 
 
Methods  
 
From 2006 – 2009, pregnant women were recruited for the study at their first 
antenatal care (ANC) visit at Mswambweni District Hospital, Mswambweni, Coast Province, 
Kenya.  At the first ANC visit, blood, stool and urine samples were collected, in addition to 
maternal anthropometrics, and basic demographic information. All women diagnosed with 
helminthes infections were treated with albendazole. Women were not treated for urogenital 
schistosomiasis during pregnancy, but treatment (e.g., praziquantel) was delayed until after 
delivery, per standard care in Kenya during the study period. All women enrolled in the study 
received IPTp-SP, iron, and multi-vitamins per Kenyan national guidelines 
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All women provided written informed consent prior to study enrollment. Institutional review 
board approval was received by Case Western Reserve University, Kenya Medical 
Research Institute, and the University of North Carolina at Chapel Hill.   
 
Measures 
 
Malaria was determined both by microscopy using the standard Gibson stain (thick 
and thin slices) and by PCR/Ligase Detection Reaction Fluorescent Microsphere Assay as 
previously described [86] at antenatal care and at delivery for maternal peripheral, cord and 
placental samples.  PCR is considered to have high sensitivity to detect malaria parasitemia; 
however, microscopy, which is more commonly used in clinical settings, is generally 
considered reliable to detect malaria in higher concentrations [83]. For this study, we used 
microscopy as a proxy for higher intensity of malaria infection and PCR-positive malaria as 
any malaria infection. 
 
Maternal stool and urine sample were collected at the first ANC visit and at delivery. 
Stool samples were tested for hookworm infection (Ancylostoma duodenale) and other STH 
(Ascaris lumbricoides, Trichuris trichuria, Strongyloides stercoralis). STH infections were 
determined by the presence of intestinal eggs in the stool sample. Burden was also 
determined by count of eggs/gram. Urine samples were evaluated for presence of urogenital 
schistosomiasis (Schistosomiasis haematobium) and results expressed as number of 
eggs/mL.  Schistosomiasis was also categorized as light (0-<50 eggs/mL) or moderate (>50 
eggs/mL), according to WHO criteria [138]. 
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Hemoglobin (Hb) levels were measured at the first ANC visit and at delivery by 
Coulter counter (Beckman Coulter Inc.). Women were classified as anemic (Hb < 11 g/dL) 
and then categorized as being moderately to severely anemic (Hb <9 g/dL) and being mildly 
to non-anemic (Hb >9 g/dL) according to the WHO classification of anemia [104].  Cord 
blood hemoglobin levels were also determined and cord (fetal) hemoglobin defined by 
hemoglobin <12.5 g/dL, as previously defined [45].   Maternal height and weight were taken 
at the first ANC visit (generally in the second trimester) and body mass index (BMI) 
calculated as kg/m2.  Since pre-pregnancy BMI was unavailable, to assess BMI, low BMI 
was defined as the lowest 10th percentile for the gestational age at measurement, which 
ranged from 19.8 to 20.7 kg/m2.  
 
Analyses were performed in SAS version 9.3 (SAS Institute, Cary, NC, USA).  
Descriptive analyses were performed. Parity, gestational age, maternal age, maternal 
education, and socio-economic status (as measured by monthly household expenditures) 
were evaluated as potential confounders, based on previous research [119,121-125].  The 
risk ratios for moderate/severe anemia associated with each of infections evaluated are 
presented with and without the potential confounders, using a log-binomial regression 
model. A backward elimination strategy was employed to estimate the adjusted RR of 
moderate/severe maternal anemia associated with infections and maternal BMI, accounting 
for the potential confounders. 
 
Results 
 
Of the 813 women screened at ANC, 706 (88%) consented women had blood and 
urine samples available for anemia, malaria, and schistosomiasis evaluation, respectively. 
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Of these participants, 544 (71%) provided stool samples at antenatal care for measurement 
of STHs.  The mean gestational age at enrollment was 24.5 weeks (SD 3.8 weeks). 
 
At the first ANC visit, 516 (71%) were anemic (Hb < 11 g/dL) and 190 (27%) had 
moderate to severe anemia (Hb <9 g/dL). For subsequent analyses, moderate/severe 
anemia was evaluated as the primary outcome of interest. About 19% of the women were 
<20 years of age, nearly 88% were married, 12% had no formal education, and about 25% 
were primagravidas (Table 1). In unadjusted analyses, these factors were not associated 
with increased risk of anemia. Insecticide-treated bednet use, malaria treatment, and 
iron/folic acid received 3 months prior to the ANC visit were also not associated with 
moderate/severe anemia risk. Few women (<2%) received anti-helminth treatment prior to 
first ANC (data not shown). 
 
The association of demographic characteristics and the prevalence at first ANC of 
hookworm infection, PCR-positive malaria (P. falciparum), and urogenital schistosomiasis 
(S. haematobium) are summarized in Table 2.  Risks of P. falciparum PCR-positive (RR 
2.29, 95% CI 1.38, 3.79), hookworm (RR 1.42, 95% CI 1.02, 1.98), and urogenital 
schistosomiasis infection (RR 2.25, 95% CI 1.66, 3.07) were higher among those <20 years 
compared to women > 20 years.  Risks for infection did not differ significantly by maternal 
education levels. Primigravidity was associated with increased risk of P. falciparum PCR-
malaria (RR 1.52, 95% CI 1.11, 2.56) and urogenital schistosomiasis (RR 1.51, 95% CI 
1.07, 1.78), but not hookworm infection.  About one-fourth (25.7%) of the women reported 
no use of insecticide-treated bednets (ITNs) prior to enrollment, which was associated with 
increased risk of malaria infection (RR 2.00, 95% CI 1.23, 3.27), but not other infections.  
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Hookworm (24%), P. falciparum PCR-malaria (8%), urogenital schistosomiasis 
(17%), and T. trichuria (10%) were the most common infections at the first ANC visit. Of 
women positive for one of these infections, about 10% were co-infected (data not shown).  
Hookworm intensity ranged from 1 to 1035 eggs/g; thus all were considered ‘light’ according 
to the WHO criteria (light defined as <1999 eggs/g). To further evaluate whether relative 
intensity of infection was associated with outcomes, we also classified the highest intensity 
of infection (>100 eggs/g) among the cohort as ‘moderate’ infection.    
 
We next examined the risk for moderate/severe maternal anemia at ANC associated 
with these infections, in unadjusted and adjusted analyses (Table 3). In analyses adjusted 
for gestational age, primagravida status and low BMI, moderate/severe anemia was 
associated with moderate hookworm infection (aRR 2.53, 95% CI 1.62, 3.92), P. falciparum 
PCR-positive and microscopy positive (aRR 1.45, 95% CI 1.01, 2.08 and aRR1.98, 95% CI 
1.17, 3.35, respectively). S. haematobium and T. trichuria, although common, were not 
significantly associated with moderate/severe anemia and few women had moderate burden 
of infection. S. stercoralis and A. lumbricodes were relatively rare (about 1% or less of the 
cohort), with no cases of moderate burden; these infections were not significantly associated 
with moderate/severe anemia at ANC, in adjusted or unadjusted analyses.  
 
For those women who delivered live, term births at the study hospital, we evaluated 
the association between infection at the first ANC visit with maternal and fetal anemia at 
delivery, as well as the association of infections detected at delivery for those who had stool 
(n=210), or urine and blood samples (n=394) available at delivery. Compared to women 
whose births were excluded (due to delivery outside the study hospital, voluntary 
discontinuance of study participation, lost to follow up, premature delivery, or non-collection 
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of samples and measurements), women whose births were included were comparable on 
socio-demographics (education level, gravidity, age, and household expenditures), maternal 
characteristics (BMI, anemia) and infection at ANC (malaria, hookworm) to those whose 
births were excluded from the study (data not shown).   
 
At delivery, 34.2% of the women had moderate/severe anemia and 18.4% of the 
neonates had fetal anemia (cord Hb <12.5 g/dL).  Moderate hookworm burden at the first 
ANC visit was associated with moderate/severe maternal anemia at delivery (aRR 2.30, 
95% CI 1.42, 3.71), but other infections at first ANC visit were not significantly associated 
with risk of maternal moderate/severe maternal anemia at delivery (Table 4).  Fetal anemia 
was not significantly associated with any of the infections, in adjusted or unadjusted 
analyses.   Of women tested for presence of hookworm, P. falciparum malaria (PCR and 
microscopy) and schistosomiasis at delivery, none of these infections were significantly 
associated with maternal or fetal anemia at delivery.   
 
We also examined the association of the anemia at ANC with anemia at delivery. 
Women with moderate/severe anemia at first ANC visit had increased risk of maternal 
anemia at delivery (unadjusted RR 3.84, 95% CI 2.94, 4.98). Fetal anemia was also 
associated with moderate/severe maternal anemia at first ANC visit and moderate/severe 
maternal anemia at delivery (RR 1.58, 95% CI 1.02, 2.45, p=0.05; RR 2.75, 95% CI 1.78, 
4.24, p <0.001, respectively) (data not shown).  
 
Finally, in a multivariate regression model to assess the infections identified as risk 
factors associated with moderate/severe maternal anemia at ANC, moderate hookworm 
(aRR 2.37, 95% CI 1.44, 3.91, p=0.0007) and P. falciparum microscopy-malaria infection 
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(and aRR 2.06, 95% CI 1.24, 3.44, p =0.005, respectively) remained significantly associated 
with moderate/severe maternal anemia at ANC, when adjusting for primigravida status and 
low maternal BMI (Table 5).  
 
Discussion 
 
Few studies have examined the burden of helminthic infection and under-nutrition in 
pregnancy on maternal and fetal anemia in malaria-endemic regions.  This is now especially 
important in areas with a declining incidence of malaria.   In this study of pregnant women at 
ANC, the prevalence of P. falciparum PCR-malaria had fallen to 9% from previous rates of 
40% at delivery reported in the same region in Kenya, prior to widespread IPTp-SP [67].  
Despite this decline in malaria, 71% of the women studied were anemic, and more than 25% 
had moderate/severe anemia in pregnancy.   Infection with hookworm (24%), and 
schistosomiasis (17%), which had less significant reductions since the previous study period 
[67], were also common, although most hookworm infections were light.  While PCR-
diagnoses is more sensitive to determine malaria infection, we evaluated both microscopy-
diagnosed malaria to assess the potential associations with higher-burden parasitemia. Both 
P. falciparum malaria as diagnosed by microscopy and moderate hookworm infections at 
ANC were associated with moderate/severe anemia at the ANC visit, while urogenital 
schistosomiasis and trichurisis and light infections were not.  This is consistent with previous 
studies finding an association with anemia among populations with higher intensity parasitic 
infection [113]. 
 
Socio-demographic factors assessed included age, gravidity, education, socio-
economic and marital status, and low BMI were not significantly associated with 
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moderate/severe maternal anemia in this cohort. However, the study was conducted among 
a relatively homogenous community, and thus these disparities may not have been large 
enough to be detectable.  One limitation was that pre-pregnancy BMI and additional 
measures of under-nutrition were not available for this cohort and thus a more sophisticated 
assessment of the relationship of nutritional intake and anemia was not possible.  While our 
findings are also consistent with research suggesting that in the context of low socio-
demographic status, even light infections such as hookworm and malaria may be associated 
with anemia [141]; however, further research is needed to address these relationships. 
 
Maternal anemia significantly affects women and children, especially in low-resource 
areas where hookworm, malaria, and other parasitic infections, in addition to poor nutritional 
intake, are common. In this study, maternal anemia was associated with increased risk of 
fetal anemia.  While fetal anemia has been less well studied, emerging research suggests 
that it may also be common in areas with high-burden of infection [110-112,143,144]. Since 
fetal and childhood anemia associated with maternal anemia potentially may lead to long-
term impaired neurologic function, a better understanding the etiology and effects of fetal 
anemia is important.  
 
Effective, safe treatments are available to prevent and treat hookworm and malaria, 
both of which were associated with maternal anemia in this study.  While numerous studies 
have evaluated preventative treatment for malaria in pregnancy, fewer have assessed anti-
helminth treatment in the context of malaria treatment. Of those that have assessed 
hookworm, the results suggested that benefit may be most pronounced among women with 
higher burden of hookworm infection [124,125,142,143]. Additionally, few studies have 
evaluated the roles of multiple infections and under-nutrition in pregnancy and interventions. 
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In a study assessing the role of malaria, hookworm, and nutrition in Uganda, malaria was 
significantly associated with maternal anemia while hookworm and nutrition were not. The 
authors speculated that this was in part due to the relatively good nutritional indicators and 
coverage of helminth treatment in the region, while malaria prevention strategies were 
limited [142]. 
 
In contrast to the Uganda study, in our study, while all women in this study received 
antenatal care including IPTp-SP for malaria, treatment for hookworm as indicated, and 
iron/folic acid, most were not enrolled until after 20 weeks gestation. Thus, even with 
relatively good antenatal care, treatment was not initiated until the second trimester at which 
time anemia was prevalent in this cohort.  Furthermore, unlike the region where this study 
was conducted and despite the international recommendations, uptake of treatment for 
hookworm, malaria, and schistosomiasis in ANC is still low in many parts of Africa [138]. In 
part, this may relate to perceptions that treatment has not been associated with improved 
pregnancy outcomes or may be harmful [136].   Given the high prevalence of anemia seen 
in our study and elsewhere and the relationship between maternal and fetal anemia, further 
research is needed to optimize interventions around pregnancy to reduce anemia and 
ultimately improve maternal and newborn health. 
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Table 5-1. Maternal socio-demographic factors by maternal anemia status at first antenatal 
care visit, cohort of pregnant women in coastal Kenya, 2006-2009 
Characteristic* Moderate/severe 
anemia  
(Hg <9) 
 
N (%) 
No/mild 
anemia 
(Hg>9) 
 
N (%) 
 
 
 
RR (95% CI)† 
Number enrolled 190 (27.0) 516 (73.0) -- 
Maternal age    
   20 – 44 154 (81.1) 420 (81.4) Referent 
   < 20  36 (18.9) 96 (18.6) 1.02 (0.75, 1.39) 
Marital status    
  Married/partner 163 (86) 453 (88)  Referent 
  Widow/divorced/single 26 (14) 58 (12) 1.05 (0.95, 1.16) 
Formal education    
 No education 43 (23) 105 (21) Referent 
 Primary education 124 (65) 344 (67) 0.99 (0.68, 1.45) 
Secondary/higher education 23 (12) 63 (12) 0.98 (0.46, 2.10) 
Gravidity    
 Multigravida 145 (77) 385 (75) Referent 
 Primigravida  42 (23) 128 (25) 0.97 (0.90, 1.04) 
Body Mass Index (BMI), 
m/kg2‡ 
   
   Low BMI  154 (84) 444 (88) Referent 
   Normal BMI 30 (16) 62 (12) 1.30 (0.94, 1.81) 
Bednet last 3 mos    
   Used bednet 134 (71) 386 (75) Referent 
   Not used bednet 53 (28) 127 (25) 1.14 (0.87, 1.50) 
Malaria treated last 3 mos    
    Treatment provided 18 (9) 53 (10) Referent 
    No treatment  171 (91) 460 (90) 1.07 (0.70, 1.63) 
Folic acid/iron-last 3 mos    
   Folic acid/iron 11 (6) 28 (5) Referent 
   No folic acid/iron 178 (94) 487 (95) 0.99 (0.96, 1.03) 
*Numbers less than total enrolled reflect missing data 
†Unadjusted Risk ratio (RR) and 95% confidence intervals (CI) 
‡Adjusted for gestational age 
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Table 5-2. Maternal characteristics and association with malaria, hookworm and urogenital schistosomiasis infection in pregnancy at 
first ANC visit, among a cohort of pregnant women, coastal Kenya, 2006 – 2009 
 Total P. 
falciparum† 
 Hookworm*  S. 
haematobium 
 
 
N (%) n (%) RR (95% CI) n (%) RR (95% CI) n (%) RR (95% CI) 
Number 706 59   129  119  
Maternal Age        
   20-44 574 (81.3) 39 (7.0) Referent 96 (22.1) Referent 80 (14.1) Referent 
   < 20 132 (18.7) 20 (16.0) 2.29 (1.38, 3.79) 33 (31.4) 1.42 (1.02, 1.98) 39 (30.5) 2.25 (1.66, 3.07) 
Formal education        
   Secondary/higher 
level 
86 (12.3) 6 (7.0) Referent 9 (15.3) Referent 12 (14.6) Referent 
   Primary education 468 (66.7) 41 (9.1) 1.30 (0.57, 2.97) 86 (23.8) 1.56 (0.83, 2.93) 80 (17.4) 1.18 (0.68, 2.08) 
   No education 148 (21.1) 12 (8.5) 1.69 (0.32, 8.80) 34 (29.1) 2.43 (0.69, 8.58) 27 (18.2) 1.41 (0.46, 4.32) 
Marital status        
  Married/partner 616 (88.0) 48 (8.1) Referent 115 (24.4) Referent 100 (16.5) Referent 
  Widow/divorced/single 84 (12.0) 10 (12.1) 1.41 (0.83, 2.40) 12 (18.7) 0.86 (0.54, 1.36) 18 (21.7) 1.18 (0.77, 1.83) 
Gravidity        
   Multigravida  529 (75.7) 39 (7.6) Referent 95 (23.6) Referent 81 (15.9) Referent 
   Primigravida 170 (24.3) 19 (11.6) 1.52 (1.11, 2.56) 33 (24.6) 1.04 (0.76, 1.47) 38 (19.4) 1.51 (1.07, 1.78) 
Maternal BMI         
    Normal BMI 598 (86.7) 51 (8.5) Referent 94 (24.8) Referent 79 (15.9) Referent 
    Low BMI  92 (13.3) 12 (8.7) 0.83 (0.35, 2.01) 16 (21.0) 1.08 (0.66, 1.78) 19 (19.4) 1.04 (0.60, 1.78) 
Bednet use last 3 mos        
    Yes 520 (74.3) 24 (13.9) Referent 94 (23.6) Referent 84 (16.2) Referent 
    No 180 (25.7) 35 (6.9) 2.00 (1.23, 3.27) 33 (23.9) 1.01 (0.72, 1.43) 34 (19.9) 1.23 (0.86, 1.76) 
*Analyses restricted to women with stool sample available at antenatal care visit (n= 544) 
†PCR-diagnosed malaria 
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Table 5-3. Prevalence of parasitic infections in pregnancy and association of moderate/severe maternal anemia (Hg<9) at first ANC 
visit, among a cohort of pregnant women in coastal Kenya, 2006 – 2009 
 
 
Infection  
N* (%) 
Moderate/severe anemia  
Unadjusted RR (95% CI) 
 
p-value 
Moderate/severe anemia 
aRR† (95% CI) 
 
p-value 
Hookworm      
   Absent 415 (76.3) Referent  Referent  
   Present 129 (23.7) 1.15 (0.86 – 1.55) 0.3 1.17 (0.88, 1.56) 0.3 
   0-< 100 eggs/g 534 (98.2)  Referent  Referent  
   >100 eggs/g 10 (1.8) 2.45 (1.60, 3.77) <0.0001 2.53 (1.62, 3.92) <0.0001 
P. falciparum      
   PCR-negative   631 (91.4) Referent  Referent  
   PCR-positive  59 (8.6) 1.38 (0.96, 2.00) 0.08 1.45 (1.01, 2.08) 0.05 
    MS-negative 516 (95.8) Referent  Referent  
    MS-positive 24 (4.6) 2.12 (1.26, 3.57) 0.004 1.98 (1.17, 3.35) 0.01 
S. haematobium      
   Absent 577 (82.9) Referent  Referent  
   Present 119 (17.1) 1.00 (0.92, 1.09) 1.0 1.00 (0.92, 1.10) 0.9 
    0-< 50 eggs/mL 670 (96.3) Referent  Referent  
   >50 eggs/mL 26 (3.7) 1.15 (0.64, 2.08) 0.6 1.23 (0.68, 2.22) 0.5 
T. trichura      
   Absent 489 (89.9) Referent  Referent  
   Present 55 (10.1) 1.06 (0.70 – 1.62) 0.8 1.10 (0.73, 1.67) 0.5 
    0-<100 eggs/g 542 (99.6) --  --  
   >100 eggs/g 2 (0.4)     
S. stercoralis      
   Absent 537 (99.1) Referent  Referent  
   Present‡  5 (0.9)  0.68 (0.12 – 3.94) 0.7 0.43 (0.07, 2.70) 0.4 
A. lumbricodes      
   Absent 535 (98.5) Referent  Referent  
   Present‡ 8 (1.5) 0.42 (0.07 – 2.66) 0.4 0.67 (0.12, 3.86) 0.7 
*Numbers differ due to missing values; †Adjusted for primagravida status, gestational age at ANC, and low maternal BMI; ‡None of 
the participants had > 50 eggs/mL; MS = Microscopy-diagnosed malaria  
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Table 5-4. Association of infections and maternal and fetal anemia at delivery, coastal Kenya, 2006 – 2009 
  Maternal moderate/severe anemia (Hb < 9 g/dl) 
at delivery 
Fetal anemia (Hb < 12.5 g/dl) 
Infection at first 
ANC 
N† (%) RR (95% CI) p-
value 
aRR (95% CI)* p-
value 
RR (95% CI) p-
value 
aRR (95% CI)* p-
value 
Hookworm          
   Negative 218 (88) Referent  Referent  Referent  Referent  
   Positive 61 (22) 0.76 (0.52, 1.12) 0.2 0.81 (0.55, 1.20) 0.3 1.10 (0.64, 1.90) 0.7 1.13 (0.65, 1.95) 0.6 
   0-<100 eggs/mL 274 (98) Referent  Referent  Referent  1.0  
   >100 eggs/mL 5 (2) 2.43 (1.52, 3.90) 0.0002 2.30 (1.42, 3.71) 0.0006 1.91 (0.58, 6.08) 0.3 1.84 (0.58, 5.84) 0.3 
P. falciparum           
   PCR-negative 310 (89) Referent  Referent  Referent  Referent  
   PCR-positive 37 (11) 1.12 (0.45, 2.78) 0.8 1.02 (0.41, 2.54) 1.0 1.58 (0.44, 5.62) 0.5 1.45 (0.43, 4.91) 0.5 
   MS-negative   326  (95) Referent  Referent  Referent  Referent  
   MS-positive  17 (5) 1.16 (0.47, 2.89) 0.7 1.08 (0.43, 2.75) 0.9 1.22 (0.44, 3.40) 0.7 1.42 (0.50, 3.97) 0.3 
S. haematobium‡          
   Negative 310 (83) Referent  Referent  Referent  Referent  
   Positive 62 (17) 1.05 (0.92, 1.19) 0.4 1.05 (0.93, 1.20) 0.4 0.75 (0.21, 2.76) 0.7 0.61 (0.17, 2.21) 0.5 
Delivery infection          
Hookworm‡           
   Negative 177 (84) Referent  Referent  Referent  Referent  
   Positive 33 (16) 1.07 (0.63, 1.82) 0.8 1.08 (0.64, 1.84) 0.8 1.14 (0.52, 2.50) 0.7 1.10 (0.51, 2.41) 0.5 
P. falciparum          
  PCR-negative 353 (89) Referent  Referent  Referent  Referent  
  PCR-positive 41 (11) 1.43 (0.94, 2.20) 0.09 1.48 (0.97, 2.27) 0.07 1.58 (0.82, 3.01) 0.2 1.60 (0.84, 3.06) 0.2 
   MS-negative   384 (97) Referent  Referent  Referent  Referent  
   MS-positive  10 (3) 1.35 (0.69, 2.60) 0.4 1.42 (0.74, 2.74) 0.3 1.66 (0.63, 4.36) 0.3 1.69 (0.64, 4.45) 0.3 
S. haematobium‡          
  Negative 244 (84) Referent  Referent  Referent  Referent  
  Positive 49 (16) 0.98 (0.63, 1.53) 0.9 0.97 (0.62, 1.53) 0.9 0.80 (0.38, 1.66) 0.5 0.74 (0.36, 1.57) 0.4 
*Adjusted for primagravida status and low BMI 
†Different denominators reflect missing samples; ‡insufficient number to assess moderate burden 
MS = Microscopy-diagnosed malaria
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Table 5-5. Factors associated with moderate/severe maternal anemia at first ANC among a cohort of pregnant women, coastal 
Kenya 2006-2009. 
 Maternal moderate/severe (Hb < 9 
g/dL)  anemia at ANC 
 aRR (95% CI) * p-value 
Hookworm (>100 eggs/g) 2.37 (1.44, 3.91) 0.0007 
P. falciparum (MS-
positive) 
2.06 (1.24, 3.44) 0.005 
Low BMI 1.25 (0.86, 1.81) 0.2 
Primigravida 0.78 (0.54, 1.11) 0.2 
*Regression model adjusted for all variables listed and gestational age 
ANC = Antenatal care; MS = microscopy 
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CHAPTER SIX 
CONCLUSIONS 
 
Overview 
 
Reports of adverse birth outcomes associated with P. falciparum malaria in 
pregnancy were first published nearly 100 years ago, with reduced birth weight and 
anemia most commonly associated with infection [1]. Since the initial reports, treatment 
that is safe, effective and low-cost has been developed. Since 2004 the World Health 
Organization (WHO) has recommended intermittent preventive treatment in pregnancy 
with sulphadoxine/pyrimethamine (IPTp-SP) and insecticide-treated bednets (ITNs) for 
all pregnant women beginning in the second trimester in Sub-Saharan Africa and other 
malaria-endemic regions.  While the IPTp-SP is effective in reducing malaria in 
pregnancy, evaluation of its public health impact on pregnancy has just begun and other 
risk factors for adverse pregnancy outcomes remain prevalent in malaria-endemic 
regions, including under-nutrition and other infections. Thus, the aim of this study was to 
assess the effects of malaria in pregnancy and their relation with known risk factors 
including under-nutrition and other parasitic infections, on pregnancy outcomes among 
women receiving the recommended preventive treatment for malaria in pregnancy.   
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Findings 
We examined birth weight and moderate/severe maternal anemia among a cohort of 
women receiving IPTp-SP at first antenatal care (ANC) visit in coastal Kenya, 2006-
2009. Among this cohort of nearly 800 women enrolled in their second trimester, a 
reduced prevalence of malaria in pregnancy (approximately 10%) were observed 
compared to the prevalence of nearly 40% found in a study from the same region in 
2000-2005, prior to widespread preventive treatment for malaria.  Furthermore, among 
those women using ITNs, malaria at first ANC visit was significantly reduced.  Malaria 
infection was associated with increased umbilical artery resistance and reduced fetal 
growth and, associated with impaired placenta, in the second trimester, but not later in 
pregnancy. The end of the second trimester is when rapid fetal weight gain occurs, and 
thus it may not be surprising that this was the primary period when significant reduced 
fetal growth measurements associated with malaria were observed. Previous research 
from the DRC found significant impact of malaria at the same gestational age. 
Furthermore, the observation of significant increased umbilical resistance early in the 
second trimester is also consistent with the gestational age where there is increasing 
uterine artery blood flow, and our findings are similar to differences reported from a 
recent study. Among women with low body mass index (BMI), a proxy for under-
nutrition, malaria detected at ANC was significantly associated with reduced birth weight 
(-370 g, 95% CI -728, -12 g, p=0.04). This finding is similar to previous research 
documenting the interaction of malaria and maternal under-nutrition. 
 
The rates of maternal anemia were high at the first ANC visit (70% and 27% for 
anemia and moderate/severe anemia, respectively). When we examined the rates of 
various infections in pregnancy, hookworm (24%), P. falciparum malaria (9%), urogenital 
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schistosomiasis (17%), and T. trichuria (10%) were the most common infections. 
Moderate/severe anemia was higher among those who were microscopy malaria-
positive (aRR 2.06, 95% CI 1.24, 3.44), and those with the higher hookworm intensity 
had increased risk of anemia (aRR 2.37, 95% CI 1.44, 3.91). Neither PCR-positive 
malaria nor low-intensity infection of hookworm was significantly associated with 
increased risk of moderate/severe anemia.  Furthermore, moderate/severe maternal 
anemia was also associated with increased risk of fetal anemia, which has been 
associated with increased risk for neurodevelopment impairment in previous research. 
 
Limitations 
 
This study had several limitations. First, birth outcomes were only measured 
among term, live births, limiting our ability to generalize the findings regarding malaria-
infection and birth weight outcomes to all pregnancies.  Thus, the study primarily 
addressed the association of malaria and IUGR-related low birth weight. Additionally, 
malaria infection was measured twice, at antenatal care and delivery, but not measured 
throughout pregnancy, thus limiting the ability to estimate potential impact of re-infection 
during pregnancy.  Maternal BMI was a proxy for under-nutrition, but because maternal 
weight was measured at first ANC visit, we were unable to use the standard pre-
pregnancy BMI or other measures to assess the maternal nutritional status. Finally, 
while both maternal and fetal hemoglobin were measured, hemoglobin estimates anemia 
but does not define the type of anemia, and thus further research may be warranted to 
explore the type of anemia observed in this population to better inform treatment. 
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Strengths 
 
Despite the limitations noted, this study was among the first to evaluate the 
associations of malaria at ANC and pregnancy outcomes, among pregnant women 
receiving IPTp-SP.  The study included several measures of malaria, assessed by PCR 
as the gold standard, as well as assessment of other infections, which afforded us the 
opportunity to conduct a comprehensive assessment of the roles of a number of 
prevalent infections during pregnancy.  Furthermore, the study utilized the gold standard, 
ultrasound measurements, which have not been widely used in research in malaria-
endemic countries to date, to assess fetal growth measurements concurrent with malaria 
status.  Finally, the study included measures of both maternal and cord hemoglobin 
levels, which allowed assessment of anemia in both the mother and the fetus/neonate. 
 
Conclusions 
 
Despite safe, effective treatments for malaria and other infections, rates of 
infection-related adverse pregnancy outcomes remain high in Sub-Saharan Africa.  
Antenatal care, when many women access the available health care system, is an 
opportunity to provide interventions. While we observed decreased malaria rates with 
IPTp-SP, approximately 10% of women were still infected with malaria at the time of 
their first ANC visit, generally in the second trimester. Women infected at ANC had 
reduced fetal growth, compared to un-infected women early in pregnancy, although 
these differences decreased later in pregnancy. While minimal differences were 
observed at birth between those who were PCR-malaria positive vs. negative at 
antenatal care, those with under-nutrition and PCR malaria-infection were at increased 
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risk.  Our findings confirm the importance of preventative treatment for malaria to reduce 
the adverse outcomes associated with P. falciparum malaria. In 2012, the WHO 
recommended IPTp-SP be provided on a monthly basis, given the research suggesting 
3 or more treatments are more effective. Additionally, our results point to the opportunity 
to further reduce rates of malaria pre-pregnancy or early in pregnancy through 
widespread use of ITNs, as suggested in other studies.  
 
Furthermore, in Sub-Saharan Africa, co-infection with other parasitic infections, 
most notably hookworm, remains common.  Thus, even with IPTp-SP, maternal anemia 
rates remain high in many areas.  In this cohort, while microscopy malaria was 
associated with moderate/severe anemia, higher-intensity hookworm infection was also 
an important risk factor that was highly associated with risk of moderate/severe anemia 
in pregnancy.  
 
Finally, while significant progress has been made to reduce malaria in 
pregnancy, our results suggest the need to not only continue current efforts, but also to 
better integrate treatment for other infections, such as hookworm, and interventions for 
under-nutrition into ANC programs that include IPTp-SP.  Comprehensive ANC 
programs incorporating malaria and prevalent conditions that reach women early in 
pregnancy are needed to continue to improve maternal and newborn outcomes in Sub-
Saharan Africa. 
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Appendix 
 
Since body mass index (BMI) generally increases over the course of pregnancy, 
additional analyses were under-taken to assess the association between gestational age 
in pregnancy and BMI. Figure A1-1 illustrates the mean (SD) of BMI by gestational age 
at antenatal care. 
 
Figure A1-1. Mean BMI (SD) by gestational age in pregnancy at first ANC visit, coastal 
Kenya, 2006 – 2009. 
 84 
 
REFERENCES 
 
[1] Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. (2007) 
Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis;7(2):93–104. 
[2] Eisele TP, Larsen DA, Anglewicz PA, Keating J, Yukich J, Bennett A, et al. 
(2012) Malaria prevention in pregnancy, birthweight, and neonatal mortality: a 
meta-analysis of 32 national cross-sectional datasets in Africa. Lancet Infect 
Dis;12(12):942–9. 
[3] Newman RD, Parise ME, Slutsker L, Nahlen B, Steketee RW. (2003) Safety, 
efficacy and determinants of effectiveness of antimalarial drugs during 
pregnancy: implications for prevention programmes in Plasmodium falciparum-
endemic sub-Saharan Africa. Trop Med Int Health;8(6):488–506. 
[4] Garner P, Gülmezoglu AM. (2006) Drugs for preventing malaria in pregnant 
women. Cochrane Database Syst Rev;(4):CD000169. 
[5] World Health Organization. (2007) Malaria in pregnancy guidelines for measuring 
key monitoring and evaluation indictors. 
http://whqlibdoc.who.int/publications/2007/9789241595636_eng.pdf.  
[6] Iriemenam NC, Shah M, Gatei W, van Eijk AM, Ayisi J, Kariuki S, et al. (2012) 
Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular 
markers in Plasmodium falciparum parasites from pregnant women in western 
Kenya. Malar J;11:134. 
[7] Likwela JL, D'Alessandro U, Lokwa BL, Meuris S, Dramaix MW. (2012) 
Sulfadoxine-pyrimethamine resistance and intermittent preventive treatment 
during pregnancy: a retrospective analysis of birth weight data in the Democratic 
Republic of Congo (DRC). Trop Med Int Health;17(3):322–9. 
[8] Offianan AT, Penali LK, Coulibaly M, Tiacoh N, Ako A, Adji E, et al. (2012) 
Comparative efficacy of uncontrolled and controlled intermittent preventive 
treatment during pregnancy (IPTp) with combined use of LLTNs in high 
resistance area to sulfadoxine-pyrimethamine in Côte d'Ivoire. Infect Drug 
Resist;5:53–63. 
[9] Hamer DH, Mwanakasale V, Macleod WB, Chalwe V, Mukwamataba D, Champo 
D, et al. (2007) Two-dose versus monthly intermittent preventive treatment of 
malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian 
women. J Infect Dis;196(11):1585–94. 
[10] Briand V, Bottero J, Noël H, Masse V, Cordel H, Guerra J, et al. (2009) 
Intermittent treatment for the prevention of malaria during pregnancy in Benin: a 
randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine 
with mefloquine. J Infect Dis;200(6):991–1001. 
[11] Gies S, Coulibaly SO, Ouattara FT, D'Alessandro U. (2009) Individual efficacy of 
intermittent preventive treatment with sulfadoxine-pyrimethamine in primi- and 
 85 
 
secundigravidae in rural Burkina Faso: impact on parasitaemia, anaemia and 
birth weight. Trop Med Int Health; 14(2):174–82. 
[12] Tiono AB, Ouedraogo A, Bougouma EC, Diarra A, Konaté AT, Nébié I, et al. 
(2009) Placental malaria and low birth weight in pregnant women living in a rural 
area of Burkina Faso following the use of three preventive treatment regimens. 
Malar J;8:224. 
[13] Valea I, Tinto H, Drabo MK, Huybregts L, Sorgho H, Ouedraogo JB, et al. (2012) 
An analysis of timing and frequency of malaria infection during pregnancy in 
relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina 
Faso. Malar J;11:71. 
[14] Mbaye A, Richardson K, Balajo B, Dunyo S, Shulman C, Milligan P, et al. (2006) 
A randomized, placebo-controlled trial of intermittent preventive treatment with 
sulphadoxine-pyrimethamine in Gambian multigravidae. Trop Med Int 
Health;11(7):992–1002. 
[15] Clerk CA, Bruce J, Affipunguh PK, Mensah N, Hodgson A, Greenwood B, et al. 
(2008) A randomized, controlled trial of intermittent preventive treatment with 
sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women 
in Ghana. J Infect Dis; 198(8):1202–11. 
[16] Tagbor H, Bruce J, Agbo M, Greenwood B, Chandramohan D. (2010) Intermittent 
screening and treatment versus intermittent preventive treatment of malaria in 
pregnancy: a randomised controlled non-inferiority trial. PLoS One;5(12):e14425. 
[17] Filler SJ, Kazembe P, Thigpen M, Macheso A, Parise ME, Newman RD, et al. 
(2006) Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine 
intermittent preventive treatment for malaria in HIV-positive and HIV-negative 
pregnant women in Malawi. J Infect Dis;194(3):286–93. 
[18] Luntamo M, Kulmala T, Mbewe B, Cheung YB, Maleta K, Ashorn P. (2010) Effect 
of repeated treatment of pregnant women with sulfadoxine-pyrimethamine and 
azithromycin on preterm delivery in Malawi: a randomized controlled trial. Am J 
Trop Med Hyg;83(6):1212–20. 
[19] Diakite OS, Kayentao K, Traoré BT, Djimde A, Traoré B, Diallo M, et al. (2011) 
Superiority of 3 over 2 doses of intermittent preventive treatment with 
sulfadoxine-pyrimethamine for the prevention of malaria during pregnancy in 
mali: a randomized controlled trial. Clin Infect Dis;53(3):215–23. 
[20] Bardají A, Sigauque B, Sanz S, Maixenchs M, Ordi J, Aponte JJ, et al. (2011) 
Impact of malaria at the end of pregnancy on infant mortality and morbidity. J 
Infect Dis;203(5):691–9. 
[21] Challis K, Osman NB, Cotiro M, Nordahl G, Dgedge M, Bergström S. (2004) 
Impact of a double dose of sulphadoxine-pyrimethamine to reduce prevalence of 
pregnancy malaria in southern Mozambique. Trop Med Int Health;9(10):1066–73. 
 
 86 
 
[22] Ndyomugyenyi R, Clarke SE, Hutchison CL, Hansen KS, Magnussen P. (2011) 
Efficacy of malaria prevention during pregnancy in an area of low and unstable 
transmission: an individually-randomised placebo-controlled trial using 
intermittent preventive treatment and insecticide-treated nets in the Kabale 
Highlands, southwestern Uganda. Trans R Soc Trop Med Hyg;105(11):607–16. 
[23] Huynh BT, Fievet N, Gbaguidi G, Dechavanne S, Borgella S, Guézo-Mévo B, et 
al. (2011) Influence of the timing of malaria infection during pregnancy on birth 
weight and on maternal anemia in Benin. Am J Trop Med Hyg;85(2):214–20. 
[24] Le Port A, Cottrell G, Dechavanne C, Briand V, Bouraima A, Guerra J, et al. 
(2011) Prevention of malaria during pregnancy: assessing the effect of the 
distribution of IPTp through the national policy in Benin. Am J Trop Med 
Hyg;84(2):270–5. 
[25] Vanga-Bosson HA, Coffie PA, Kanhon S, Sloan C, Kouakou F, Eholie SP, et al. 
(2011) Coverage of intermittent prevention treatment with sulphadoxine-
pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire. 
Malar J;10:105. 
[26] Bouyou-Akotet MK, Nzenze-Afene S, Ngoungou EB, Kendjo E, Owono-Medang 
M, Lekana-Douki JB, et al. (2010) Burden of malaria during pregnancy at the 
time of IPTp/SP implementation in Gabon. Am J Trop Med Hyg;82(2):202–9. 
[27] Ramharter M, Schuster K, Bouyou-Akotet MK, Adegnika AA, Schmits K, Mombo-
Ngoma G, et al. (2007) Malaria in pregnancy before and after the implementation 
of a national IPTp program in Gabon. Am J Trop Med Hyg;77(3):418–22. 
[28] Hommerich L, von Oertzen C, Bedu-Addo G, Holmberg V, Acquah PA, Eggelte 
TA, et al. (2007) Decline of placental malaria in southern Ghana after the 
implementation of intermittent preventive treatment in pregnancy. Malar J;6:144. 
[29] Wilson NO, Ceesay FK, Obed SA, Adjei AA, Gyasi RK, Rodney P, et al. (2011) 
Intermittent preventive treatment with sulfadoxine-pyrimethamine against malaria 
and anemia in pregnant women. Am J Trop Med Hyg;85(1):12–21. 
[30] Feng G, Simpson JA, Chaluluka E, Molyneux ME, Rogerson SJ. (2010) 
Decreasing burden of malaria in pregnancy in Malawian women and its 
relationship to use of intermittent preventive therapy or bed nets. PLoS One; 
5(8):e12012. 
[31] Kapito-Tembo A, Meshnick SR, van Hensbroek MB, Phiri K, Fitzgerald M, 
Mwapasa V. (2011) Marked reduction in prevalence of malaria parasitemia and 
anemia in HIV-infected pregnant women taking cotrimoxazole with or without 
sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in 
Malawi. J Infect Dis;203(4):464–72. 
[32] Brentlinger PE, Dgedge M, Correia MA, Rojas AJ, Saúte F, Gimbel-Sherr KH, et 
al. (2007) Intermittent preventive treatment of malaria during pregnancy in central 
Mozambique. Bull World Health Organ;85(11):873–9. 
 87 
 
[33] Falade CO, Tongo OO, Ogunkunle OO, Orimadegun AE. (2010) Effects of 
malaria in pregnancy on newborn anthropometry. J Infect Dev Ctries;4(7):448–
53. 
[34] Aribodor DN, Nwaorgu OC, Eneanya CI, Okoli I, Pukkila-Worley R, Etaga HO. 
(2009) Association of low birth weight and placental malarial infection in Nigeria. 
J Infect Dev Ctries;3(8):620–3. 
[35] Tongo OO, Orimadegun AE, Akinyinka OO. (2011) Utilisation of malaria 
preventive measures during pregnancy and birth outcomes in Ibadan, Nigeria. 
BMC Pregnancy Childbirth;11:60. 
[36] Aziken ME, Akubuo KK, Gharoro EP. (2011) Efficacy of intermittent preventive 
treatment with sulfadoxine-pyrimethamine on placental parasitemia in pregnant 
women in midwestern Nigeria. Int J Gynecol Obstet;112(1):30–3. 
[37] Sarr D, Marrama L, Gaye A, Dangou JM, Niang M, Mercereau-Puijalon O, et al. 
(2006) High prevalence of placental malaria and low birth weight in Sahelian 
periurban area. Am J Trop Med Hyg;75(1):171–7. 
[38] Olliaro PL, Delenne H, Cisse M, Badiane M, Olliaro A, Vaillant M, et al.(2008)  
Implementation of intermittent preventive treatment in pregnancy with 
sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural 
Senegal. Malar J;7:234. 
[39] Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE. (2011) 
Intermittent treatment to prevent pregnancy malaria does not confer benefit in an 
area of widespread drug resistance. Clin Infect Dis;53(3):224–30. 
[40] Mbonye AK, Bygbjerg IC, Magnussen P. (2008) Intermittent preventive treatment 
of malaria in pregnancy: a new delivery system and its effect on maternal health 
and pregnancy outcomes in Uganda. Bull World Health Organ;86(2):93–100. 
[41]  Steketee RW, Campbell CC. (2010) Impact of national malaria control scale-up 
programmes in Africa: magnitude and attribution of effects. Malaria Journal, 
9:299  
[42]  World Health Organization. Updated WHO Policy Recommendation (2012). 
Intermittent Preventive Treatment of malaria in pregnancy using 
Sulfadoxine/Pyrimethamine (IPTp-SP). 
http://www.who.int/malaria/iptp_sp_updated_policy_recommendation_en_10201
2.pdf   
[43] de Benoist B, McLean E, Egli I, Cogswell M. (2008) Worldwide prevalence of 
anaemia 1993–2005 WHO global database on anaemia . Geneva: World Health 
Organization.  
 
[44] Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. (2006) WHO 
analysis of causes of maternal death: a systematic review. Lancet 
2006;367(9516):1066-74. 
 
 88 
 
[45] Rogawski ET, Chaluluka E, Molyneux ME, Feng G, Rogerson SJ, Meshnick SR. 
(2012) The effects of malaria and intermittent preventive treatment during 
pregnancy on fetal anemia in Malawi. Clin Infect Dis;55(8):1096-102. 
 
[46] Mwinga K, Vermund SH, Chen YQ, Mwatha A, Read JS, Urassa W, Carpenetti 
N, Valentine M, Goldenberg RL. (2009) Selected hematologic and biochemical 
measurements in African HIV-infected and uninfected pregnant women and their 
infants: the HIV Prevention Trials Network 024 protocol. BMC Pediatr ;9:49. doi: 
10.1186/1471-2431-9-49. 
 
[47] Brabin BJ, Kalanda BF, Verhoeff FH, Chimsuku LH, Broadhead RL. (2004) Risk 
factors for fetal anaemia in a malarious area of Malawi. Ann Trop Paediatr; 
24:311–21. 
 
[48] Felt BT, Peirano P, Algarín C, Chamorro R, Sir T, Kaciroti N, Lozoff B. (2012) 
Long-term neuroendocrine effects of iron-deficiency anemia in infancy. Pediatr 
Res.;71(6):707-12. 
 
[49] Cao C, O’Brien KO. (2013) Pregnancy and iron homeostasis: an update. 
Nutrition Reviews 71(1):35–51. 
 
[50] Mei Z, Cogswell ME, Parvanta I, Lynch S, Beard JL, Stoltzfus RJ, Grummer-
Strawn LM. (2005) Hemoglobin and ferritin are currently the most efficient 
indicators of population response to iron interventions: an analysis of nine 
randomized controlled trials. J Nutr;135(8):1974-80. 
 
[51] Viteri FE. The consequences of iron deficiency and anemia in pregnancy. (1994) 
In: Allen L, King J, Lonnerdahl B, eds. Nutrient regulation during pregnancy, 
lactation and growth. New York: Plenum Press, 127–139. 
 
[52] Goonewardene M, Shehata M, Hamad A. (2012) Anaemia in pregnancy. Best 
Pract Res Clin Obstet Gynaecol;26(1):3-24.  
 
[53] Scholl TO. (2005) Iron status during pregnancy: setting the stage for mother and 
infant. Am J Clin Nutr;81(5)1218 S-1222 S. 
 
[54] Gangopadhyay R, Karoshi M, Keith L. (2011) Anemia and pregnancy: a link to 
maternal chronic diseases. Int J Gync 115: S11-S15. 
 
[55] Alusala DN, Estambale BB, Magnussen P, Friis H, Luoba AI, Mwaniki D. 
Predictors of serum ferritin and haemoglobin during pregnancy, in a malaria-
endemic area of western Kenya.Ann Trop Med Parasitol. 2008 Jun;102(4):297-
308. 
 
[56] Adam I, Babiker S Mohmmed AA, Salih MM, Prins MH, Zaki M. (2008) Low body 
mass Index, anaemia and poor perinatal outcome in a rural hospital in Eastern 
Sudan. Journal of Tropical Pediatrics; 54 (3): 202-204. 
 
 89 
 
[57]     Ouédraogo S, Koura GK, Accrombessi MM, Bodeau-Livinec F, Massougbodji A, 
Cot M. (2012) Maternal anemia at first antenatal visit: prevalence and risk factors 
in a malaria-endemic area in Benin. Am J Trop Med Hyg;87(3):418-24 
 
[58] Boel M, Carrara VI, Rijken M, Proux S, Nacher M, Pimanpanarak M, Paw MK, 
Moo O, Gay H, Bailey W, Singhasivanon P, White NJ, Nosten F, McGready R. 
(2010) Complex Interactions between soil-transmitted helminths and malaria in 
pregnant women on the Thai-Burmese border. PLoS Negl Trop Dis ;4(11):e887.  
 
[59] Schaible UE, Kaufmann SHE. (2007) Malnutrition and Infection: Complex 
mechanisms and global impacts. Plos Med. 115. 
 
[60] Landis SH, Lokomba V, Ananth CV, Atibu J, Ryder RW, Hartmann KE, Thorp 
JM, Tshefu A, Meshnick SR. (2009) Impact of maternal malaria and under-
nutrition on intrauterine growth restriction: a prospective ultrasound study in 
Democratic Republic of Congo. Epidemiol Infect;137(2):294-304. 
 
[61] OurMason JB, Saldanha LS, Ramakrishnan U, Lowe A, Noznesky EA, Girard 
AW, McFarland DA, Martorell R. (2012) Opportunities for improving maternal 
nutrition and birth outcomes: synthesis of country experiences. Food Nutr 
Bull;33(2 Suppl):S104-37. 
 
[62]  Mehta S, Manji KP, Young AM, Brown ER, Chasela C, Taha TE, Read JS, 
Goldenberg RL, Fawzi WW. (2008) Nutritional indicators of adverse pregnancy 
outcomes and mother-to-child transmission of HIV among HIV-infected women. 
Am J Clin Nutr 87(6):1639-49. 
 
[63] Ayoya MA, Spiekermann-Brouwer GM, Traoré AK, Stoltzfus RJ, Garza C. (2006) 
Determinants of anemia among pregnant women in Mali. Food Nutr Bull;27(1):3-
11. 
 
[64] Muhangia L, Woodburn P, Omarab M, Omoding N, Kizito D, Mpairwe H, 
Nabulime J, Ameke C, Morison LA, Elliott AM. (2007) Associations between mild-
to-moderate anaemia in pregnancy and helminth, malaria and HIV infection in 
Entebbe, Uganda. Trans R Soc Trop Med Hyg; 101(9):899-907. 
 
[65] Baig-Ansari N, Badruddin SH, Karmaliani R, Harris H, Jehan I, Pasha O, Moss N, 
McClure EM, Goldenberg RL. (2008) Anemia prevalence and risk factors in 
pregnant women in an urban area of Pakistan. Food Nutr Bull ;29(2):132-9. 
 
[66] Stoltzfus RJ, Dreyfuss ML; International Nutritional Anemia Consultative Group 
(1998) Guidelines for the Use of Iron Supplements to Prevent and Treat Iron 
Deficiency Anemia. Geneva: World Health Organization. 
 
[67] Fairley JK, Bisanzio D, King CH, Kitron U, Mungai P, Muchiri E, King CL, 
Malhotra I. (2013) Birthweight in offspring of mothers with High Prevalence of 
Helminth and Malaria infection in Coastal Kenya. Am J Trop Med Hyg;88(1):48-5. 
 
 90 
 
[68] Brooker S, Hotez PJ, Bundy DAP. (2008). Hookworm-related anaemia among 
pregnant women: a systematic review. Plos Neg Trop Dis 2 (9): e291. 
 
[69]  WHO. (1994) Report of the WHO informal consultation on hookworm infection 
and anaemia in girls and women. WHO/CTD/SIP/96.1. World Health 
Organization, Geneva. 
 
[70]  Montresor DWT, Crompton A, Hall DAP, Bundy, Savioli L. (1998) Guidelines for 
the evaluation of soil-transmitted helminthiasis and schistosomiasis at community 
level. WHO/CTD/SIP/98.1 
[71] WHO. (2002) Prevention and Control of Schistosomiasis and Soil-Transmitted  
Helminthiasis: Report of a WHO Expert Committee. Geneva: World Health 
Organization; 2002. 
[72]  WHO. (2002) Report of the WHO informal consultation on the use of praziquantel 
during pregnancy/lactation and albendazole/mebendazole in children under 24 
months.  Geneva: World Health Organization. WHO/CDS/CPE/PVC/2002.4. 
[73] Haider BA, Humayun, Q, Bhutta ZA. (2009). Effect of administration of 
antihelminthics for soil transmitted helminths during pregnancy. Cochrane 
Database of Systematic Reviews (2), CD005547. 
 
[74] Larocque R, Casapia M, Gotuzzo E, MacLean JD, Soto JC, Rahme E, Gyorkos, 
TW. (2006) A double-blind randomized controlled trial of antenatal mebendazole 
to reduce low birthweight in a hookworm-endemic area of Peru. Trop Med Int 
Health 11: 1485–1495. 
 
[75] Elliott AM, Ndibazza J, Mpairwe H, Muhangi L, Webb EL, Kizito D, et al. (2011) 
Treatment with anthelminthics during pregnancy: what gains and what risks for 
the mother and child? Parasitology 138: 1499-1507.  
 
[76] Torlesse, H. and Hodges, M. (2001) Albendazole therapy and reduced decline in 
haemoglobin concentration during pregnancy (Sierra Leone). Trans Royal 
Society Trop Med Hygiene 95: 195–201. 
 
[77] Ndibazza J, Muhangi L, Akishule D, Kiggundu M, Ameke C, Oweka J, Kizindo R, 
Duong T,  Kleinschmidt I, Muwanga M, Elliott AM. (2010) Effects of Deworming 
during Pregnancy on Maternal and Perinatal Outcomes in Entebbe, Uganda: A 
Randomized Controlled Trial. Clin Infect Dis; 50(4): 531–540. 
 
[76] Nour NM. (2010) Schistosomiasis: health effects on women. Rev Obstet 
Gynecol; 3(1):28-32. 
 
[77] Gyorkos TW, Gilbert NL, Larocque R, Casapía M. (2011) Trichuris and 
hookworm infections associated with anaemia during pregnancy. Trop Med Int 
Health;16(4):531-7. 
 
[78]  Edmonds FH. (1899) Malaria and pregnancy; Br Med J. 1(2000): 1023.  
 91 
 
[79] Study registration available at Clinical Trials.gov: 
http://clinicaltrials.gov/ct2/show/NCT00314899?term=fetal+immunity%2C+king&r
ank=1   
[80] Mutuku FM, King CH, Mungai P, Mbogo C, Mwangangi J, Muchiri EM, Walker 
ED, Kitron U. (2011) Impact of insecticide-treated bed nets on malaria 
transmission indices on the south coast of Kenya. Malar J 10:356.  
[81]   Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO. (2010) Quantifying 
the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS 
Med;7(1):e1000221. 
[82]  Peters PJ, Thigpen MC, Parise M, Newman RD. (2007) Safety and toxicity of 
sulfadoxine-pyrimethamine: implications for prevention of malaria in pregnancy 
using intermittent preventive treatment. Drug safety; 30: 481-6.   
[83]  Kattenberg JH, Ochodo EA, Boer KR, Schallig HD, Mens PF, Leeflang MM. 
(2011) Systematic review and meta-analysis: rapid diagnostic tests versus 
placental histology, microscopy and PCR for malaria in pregnant women. Malar J 
10:321. 
[84] Campos IM, Uribe ML, Cuesta C, Franco-Gallego A, Carmona-Fonseca J, 
Maestre A. (2011) Diagnosis of gestational, congenital, and placental malaria in 
Colombia: comparison of the efficacy of microscopy, nested polymerase chain 
reaction, and histopathology. Am J Trop Med Hyg;84(6):929-35. 
[85]  Rantala AM, Taylor SM, Trottman PA, Luntamo M, Mbewe B, Maleta K, Kulmala 
T, Ashorn P, Meshnick SR. (2010) Comparison of real-time PCR and microscopy 
for malaria parasite detection in Malawian pregnant women. Malar J 9:269. 
[86]  McNamara DT, et al. (2006) Diagnosing infection levels of four human malaria 
parasite species by a polymerase chain reaction/ligase detection reaction 
fluorescent microsphere-bassed assay. Am J Trop Med Hyg 74: 413-421. 
[87] Hadlock FP, Harrist RB, Martinez-Poyer J. (1991) In utero analysis of fetal 
growth: a sonographic weight standard. Radiology 181:129–133. 
[88] Rohrer, F. (1921) "Der Index der Körperfülle als Maß des Ernährungszustandes” 
[89] Brabin B. (1992) Fetal anaemia in malarious areas: its causes and significance. 
Ann Trop Paediatr  12:303–10.  
 
[90] McLean E, Egli I, Cogswell M (ed). (2012) Worldwide prevalence of anaemia 
1993–2005: WHO global database on anaemia. Geneva: World Health 
Organization. 
[91] Institute of Medicine. (2009)Weight gain and pregnancy. Washington DC.  
 92 
 
[92]  Ngnie-Teta I, Kuate-Defo B, Receveur O. (2009) Multilevel modelling of 
sociodemographic predictors of various levels of anaemia among women in Mali. 
Public Health Nutr; 12(9):1462-9. 
[93] Steketee RW, Nahlen BL, Parise ME, Menendez C. (2001) The burden of 
malaria in pregnancy in malaria-endemic areas. American Journal of Tropical 
Medicine and Hygiene;64(1-2 Suppl):28-35.  
[94] Marchant T, Willey B, Katz J, Clarke S, Kariuki S, ter Kuile F, Lusingu J, 
Ndyomugyenyi R, Schmiegelow C, Watson-Jones D, Armstrong Schellenberg J. 
(2012) Neonatal mortality risk associated with preterm birth in East Africa, 
adjusted by weight for gestational age: individual participant level meta-analysis. 
PLoS Med 9(8):e1001292. 
[95] Steketee RW, Campbell CC. (2010) Impact of national malaria control scale-up 
programmes in Africa: magnitude and attribution of effects. Malaria Journal; 
9:299. 
[96] Neggers Y, Goldenberg RL. (2003) Some thoughts on body mass index, 
micronutrient intakes and pregnancy outcome. Journal of Nutrition; 133: 1737S-
1740S. 
[97] Caulfield LE, Richard SA, Black RE. (2004) Undernutrition as an underlying 
cause of malaria morbidity and mortality in children less than five years old. Am J 
Trop Med Hyg. 2004 Aug;71(2 Suppl):55-63 
[98] Kalilani L, Mofolo I, Chaponda M, Rogerson SJ, Meshnick SR. (2010) The effect 
of timing and frequency of Plasmodium falciparum infection during pregnancy on 
the risk of low birth weight and maternal anemia. Trans Royal Society of Tropical 
Medicine and Hygiene;104:416-422. 
[99] Griffin JB, Lokomba V, Landis SH, Thorp JM Jr, Herring AH, Tshefu AK, 
Rogerson SJ, Meshnick SR. (2012) Plasmodium falciparum parasitaemia in the 
first half of pregnancy, uterine and umbilical artery blood flow, and foetal growth: 
a longitudinal Doppler ultrasound study. Malaria Journal 11:319. 
[100] Rijken MJ, Papageorghiou AT, Thiptharakun S, Kiricharoen S, Dwell SL, 
Wiladphaingern J, Pimanpanarak M, Kennedy SH, Nosten F, McGready R. 
(2012) Ultrasound evidence of early fetal growth restriction after maternal malaria 
infection. PLoS One 7:e31411.  
[101] Schmiegelow C, et al. (2013) Malaria and fetal growth alterations in the 3(rd) 
trimester of pregnancy: A longitudinal ultrasound study. PLoS One;8:e53794. 
[102] Trudinger BJ, Giles WB, Cook CM, Bombardieri J, Collins LE. (1985) Fetal 
umbilical artery flow velocity waveforms and placental resistance: clinical 
significance. British Journal of Obstetrics and Gynaecology  92:23–30. 
 93 
 
[103] Kayatentao K, Garner P, van Eijk AM, Naidoo I, Roper C, Mulokozi A, MacArthur 
JR, Luntamo M, Ashorn P, Doumbo OK, ter Kuile FO. (2013) Intermittent 
preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of 
sulfadoxine-pyrimethamine and risk of low birth weight in Africa: Systematic 
review and meta-analysis. JAMA;309:594-604. 
[104]  McLean E, Egli I, Cogswell M (ed). (2012) Worldwide prevalence of anaemia 
1993–2005: WHO global database on anaemia. Geneva: World Health 
Organization. 
[105]  Ouédraogo S, Koura GK, Accrombessi MM, Bodeau-Livinec F, Massougbodji A, 
Cot M. (2012) Maternal anemia at first antenatal visit: prevalence and risk factors 
in a malaria-endemic area in Benin. Am J Trop Med Hyg 87:418-424. 
[106]  Nwizi EN, Iliyasu Z, Ibrahim SA, Galadanci HS. (2011) Socio-demographic and 
maternal factors in anaemia in pregnancy at booking in Kano, Northern Nigeria. 
African Journal of Reproductive Health 15: 33-41.  
[107]  Hartman TK, Rogerson SJ, Fischer PR. (2010) The impact of maternal malaria 
on newborns. Ann Trop Paediatr 30:271-282 
[108]  Koura GK, Ouedraogo S, Le Port A, Watier L, Cottrell G, et al. (2012) Anaemia 
during pregnancy: impact on birth outcome and infant haemoglobin level during 
the first 18 months of life. Trop Med Int Health 17:283-291. 
[109]  Adediran A, Gbadegesin A, Adeyemo TA, Akinbami A, Osunkalu VO, et al. 
(2011) Haemoglobin and ferritin concentrations in cord blood in a tertiary health 
centre in Nigeria. Nig Q J Hosp Med 21:284-9. 
[110]  Chang S, Zeng L, Brouwer ID, Kok FJ, Yan H. (in press) Effect of iron deficiency 
anemia in pregnancy on child mental development in rural China. Pediatrics. 
[111]  Tamura T, Goldenberg RL, Hou J, Johnston KE, Cliver SP, et al. (2002) Cord 
serum ferritin concentrations and mental and psychomotor development of 
children at five years of age. J Pediatr 140:165-70. 
[112]  Walker SP, Wachs TD, Gardner JM, Lozoff B, Wasserman GA, Pollitt E, Carter 
JA; International Child Development Steering Group. (2007) Child development: 
risk factors for adverse outcomes in developing countries. Lancet 369(9556):145-
57. 
[113]  Brooker S, Hotez PJ, Bundy DA. (2008) Hookworm-related anaemia among 
pregnant women: a systematic review. PLoS Negl Trop Dis 2:e291.  
[114]  McClure EM, Goldenberg RL, Dent AE, Meshnick SR. (2013) A systematic 
review of the impact of prevention of malaria in pregnancy on low birth weight 
and maternal anemia. Int J Gynec Obst. doi:pii: S0020-7292(13)00051-9. 
10.1016/j.ijgo.2012.12.014 
 94 
 
[115]  Uneke CJ. (2007) Impact of placental Plasmodium falciparum malaria on 
pregnancy and perinatal outcome in sub–Saharan Africa: II: effects of placental 
malaria on perinatal outcome; malaria and HIV. Yale J Biol Med 80:95–103. 
[116]  Ouédraogo S, Bodeau-Livinec F, Briand V, Huynh BT, Koura GK, et al. (2012) 
Malaria and gravidity interact to modify maternal haemoglobin concentrations 
during pregnancy. Malar J 11:348. 
[117]  Valea I, Tinto H, Drabo MK, Huybregts L, Sorgho H, et al; FSP/MISAME study 
Group. (2012) An analysis of timing and frequency of malaria infection during 
pregnancy in relation to the risk of low birth weight, anaemia and perinatal 
mortality in Burkina Faso. Malar J 11:71. 
[118]  Degarege A, Legesse M, Medhin G, Animut A, Erko B. (2012) Malaria and 
related outcomes in patients with intestinal helminths: a cross-sectional study. 
BMC Infect Dis 12:291.  
[119]  Ouma P, van Eijk AM, Hamel MJ, Parise M, Ayisi JG, Otieno K, et al. (2007) 
Malaria and anaemia among pregnant women at first antenatal clinic visit in 
Kisumu, western Kenya. Trop Med Int Health 12(12):1515-23. 
[120]  Bustinduy AL, Parraga IM, Thomas CL, Mungai PL, Mutuku F, et al. (in press) 
Impact of polyparasitic infections on anemia and undernutrition among Kenyan 
children living in a schistosoma haematobium-endemic area. Am J Trop Med Hyg 
20.  
[121]  Sousa-Figueiredo JC, Gamboa D, Pedro JM, Fançony C, Langa AJ, Magalhães 
RJ, et al. (2012) Epidemiology of malaria, schistosomiasis, geohelminths, anemia 
and malnutrition in the context of a demographic surveillance system in northern 
Angola. PLoS One 7: e33189.  
[122]  Adegnika AA, Ramharter M, Agnandji ST, Ngoa UA, Issifou S, et al. (2010) 
Epidemiology of parasitic co-infections during pregnancy in Lambarene, Gabon. 
Trop Med Int Health 15: 1204-9. 
[123]  Awasthi S, Bundy DAP, Savioli L. Helminthic infections. (2003) BMJ 327: 431-3. 
[124]  Roberts T, Gravett CA, Velu PP, Theodoratou E, Wagner TA, Zhang JS, et al. 
(2011) Epidemiology and aetiology of maternal parasitic infections in low- and 
middle-income countries. J Glob Health 1:189-200. 
[125]  Hillier SD, Booth M, Muhangi L, Nkurunziza P, Khihembo M, et al. (2008) 
Plasmodium falciparum and helminth coinfection in a semi urban population of 
pregnant women in Uganda. J Infect Dis 198:920-927. 
 95 
 
[126]  Yatich NJ, Jolly PE, Funkhouser E, Agbenyega T, Rayner JC, et al. (2010) The 
effect of malaria and intestinal helminth co-infection on birth outcomes in Kumasi, 
Ghana.  Infect Dis Obstet Gynecol 350763. 
[127]  Montresor A, Crompton DWT, Hall A, Bundy, DAP Savioli L. (1998) Guidelines 
for the evaluation of soil-transmitted helminthiasis and schistosomiasis at 
community level. Geneva: WHO. 
[128]  Friedman JF, Mital P, Kanzaria HK, Olds GR, Kurtis JD. (2007) Schistosomiasis 
and pregnancy. Trends Parasitol ;23(4):159-64.  
[129]  Ogbodo SO, Nwagha UI, Okaka AN, Ogenyi SC, Okoko RO, Nwagha TU. 
Malaria parasitaemia among pregnant women in a rural community of eastern 
Nigeria; need for combined measures. Niger J Physiol Sci. 2009 Dec;24(2):95-
100. 
[130] Bechir M, Schelling E, Hamit MA, Tanner M, Zinsstag J. (2010) Parasitic 
infections, anemia and malnutrition among rural settled and mobile pastoralist 
mothers and their children in Chad. Ecohealth;9(2):122-3127.  
[131]   Woodburn PW, Muhangi L, Hillier S, Ndibazza J, Namujju PB, Kizza M, Ameke 
C, Omoding NE, Booth M, Elliott AM. (2009) Risk Factors for helminth, malaria, 
and HIV infection in pregnancy in Entebbe, Uganda. Plos Neg Trop Dis; 3(6): 
e473. 
 
[132]  van Eijk AM, Lindblade KA, Odhiambo F, Peterson E, Rosen DH, Karanja D, et 
al. (2009) Geohelminth infections among pregnant women in rural western 
Kenya; a cross-sectional study. PLoS Negl Trop Dis;3(1):e370.  
 
[133] Ouédraogo S, Koura GK, Bodeau-Livinec F, Accrombessi MM, Massougbodji A, 
Cot M. (in press) Maternal anemia in pregnancy: Assessing the effect of routine 
preventive measures in a malaria-endemic area. Am J Trop Med Hyg.  
 
[134]  Haider BA, Humayun Q, Bhutta ZA. (2009) Effect of administration of 
antihelminthics for soil transmitted helminths during pregnancy. Cochrane 
Database Syst Rev 2:CD005547. 
[135]  Ndibazzza J, Muhangi L, Akishule D, Kiggundu M, Ameke C, et al. (2010) Effects 
of deworming during pregnancy on maternal and perinatal outcomes in Entebbe, 
Uganda: a randomized controlled trial. CID; 50: 531-539. 
[136]  Elliott AM, Ndibazza J, Mpairwe H, Muhangi L, Webb EL, Kizito D, et al. (2011) 
Treatment with anthelminthics during pregnancy: what gains and what risks for 
the mother and child? Parasitology 138: 1499-1507. 
[137]  WHO (1994) Report of the WHO informal consultation on hookworm infection 
and anaemia in girls and women. WHO/CTD/SIP/96.1. World Health 
Organization, Geneva. 
 96 
 
 
[138] WHO (2002) Prevention and Control of Schistosomiasis and Soil-Transmitted 
Helminthiasis: Report of a WHO Expert Committee. Geneva: World Health 
Organization; 2002. 
[139]  WHO (2002) Report of the WHO informal consultation on the use of praziquantel 
during pregnancy/lactation and albendazole/mebendazole in children under 24 
months.  Geneva: World Health Organization 2002. 
WHO/CDS/CPE/PVC/2002.4. 
[140]  Basra A, Mombo-Ngoma G, Melser MC, Diop DA, Würbel H, et al. (in press) 
Efficacy of Mefloquine intermittent preventive treatment in pregnancy against 
Schistosoma haematobium infection in Gabon: A nested randomized controlled 
assessor-blinded clinical Trial. Clin Infect Dis. 40.  
[141] Gyorkos TW, Gilbert NL, Larocque R, Casapía M, Montresor A. (2012) Re-
visiting Trichuris trichiura intensity thresholds based on anemia during 
pregnancy. PLoS Negl Trop Dis ;6(9):e1783.  
[142]   Muhangi L, Woodburn P, Omara M, Omoding N, Kizito D, Mpairwe H, Nabulime 
J, Ameke C, Morison LA, Elliott AM. (2007) Associations between mild-to-
moderate anaemia in pregnancy and helminth, malaria and HIV infection in 
Entebbe, Uganda. Royal Soc Trop Med Hyg 101: 899-907. 
[143]  Makhoul Z, Taren D, Duncan B, Pandey P, Thomson C, Winzerling J, et al. 
(2012) Risk factors associated with anemia, iron deficiency and iron deficiency 
anemia in rural Nepali pregnant women. Southwest Asian J Trop Med Public 
Health;43(3):735-46. 
 
 
